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Editor's Note: We Are Providing You the Health Policy Newsletter 
To keep Bulletin readers informed about Jefferson, while containing mail 
costs, another publication is being shipped with the Bulletin. We believe 
you'll find that the Health Policy Newsletter tells you about topics that 
supplement those in the Bulletin. The Health Policy Newsletter is shipped 
quarterly, and describes health policy questions that Jefferson is studying. 
Please let us know your thoughts by directing them to 
Attention: Editor, Alumni Bulletin 
Jefferson Medical College 
1020 Locust M-41 
Phila., PA 19107 
Phone: 215 955 7920 
Fax: 215 923 9916 
Email: Malcolm.Clendenin@maiLtju.edu 
Can You Share Your Jeff Experience 41 
with a Potential Student in Your Area? 
There may be students in your geographic region who have been admitted 
to Jefferson Medical College, but are still in the process of deciding whether to 
attend Jefferson or another medical school. Benjamin Bacharach '56, Associate 
Dean for Alumni Relations and Acting Executive Director of the Alumni 
Association, urges you to talk with them about your Jefferson experience. 
The Alumni Office will put you in touch with specific students. Simply fill out 
the form below and return it to JMC Alumni Office, 1020 Locust Street M-41, 
Philadelphia, PA 19107. 
Name 
	
 Class Year or Jeff Affiliation 
Mailing Address 	  
Upcoming Events 
December 10, Friday at 8 P.M. 
Free public concert by Thomas Jefferson University Choir and Orchestra 
Conducted by Robert Sataloff '75 
First Baptist Church, 17th and Sansom Streets 
January 11, Tuesday 
Alumni reception with Paul C. Brucker, M.D., President of 
Thomas Jefferson University, in San Diego 
January 12, Wednesday 
Alumni reception with Dr. Brucker in Los Angeles 
January 14, Friday 
Alumni reception with Dr. Brucker in Honolulu 
January 19, Wednesday 
Alumni reception for first year students, in Jefferson Alumni Hall 
January 20-28 
Cruise to the Canary Islands with Jeff alumni 
January 27, Thursday 
Alumni Executive Committee meeting 
February 5-12 
CME and Ski meeting, Telluride, Colorado 
March 10, Friday 
Parents Day for sophomores 
March 16, Thursday 
Jefferson Center for Integrative Medicine event with Andrew Weil, M.D. 
in Philadelphia 
City 	
 State 	  Zip 	 March 23, Thursday 
Daytime Phone 
	 Alumni Executive Committee meeting 
I would be willing to talk with students who are deciding whether to attend Jefferson. 	 April 15, Saturday 
TJUH Women's Board Jefferson Ball in Philadelphia 
Can You Host a Student Interviewing 
or Doing a Rotation in Your Area? 
Students will be contacting alumni during November, December, and January 
requesting housing while they are interviewing for residencies. They may be 
calling at other times of the year when they are doing a clinical rotation at a 
hospital in your area (as part of their third and fourth years of medical school). 
Alumni have found that this is a fun way to catch up on what's happening at Jeff, 
and to meet physicians-to-be who may eventually be practicing in their region. 
If you would be willing to host a Jefferson student, please return the form below 
to JMC Alumni Office, 1020 Locust Street M-41, Philadelphia, PA 19107. 
Name 	
 Class Year or Jeff Affiliation 
Mailing Address 	  
City 	
 State 	  Zip 
Daytime Phone 	  
I would be willing to host a student interviewing or doing a rotation in my area 
April 27, Thursday 
Alumni annual business meeting 
May 15, Monday 
Alumni reception with Dean and Senior Vice President for Academic Affairs 
Joseph S. Gonnella, M.D., at the Stanford Inn, Palo Alto, CA 
May 16, Tuesday 
Alumni reception with Dr. Gonnella in Sacramento, CA 
May 17, Wednesday 
Alumni reception with Dr. Gonnella in San Francisco 
May 18, Thursday 
Alumni reception with Dr. Gonnella in Denver 
Reunion Weekend 2000 
June 9, Friday, alumni banquet 
June 10, Saturday, clinic presentations, reunion parties 
Bringing Cancer Knowledge 
From the Laboratory to the Bedside 	 4 
Increasing the Effectiveness of Radiotherapies 
	 6 
Molecular Pathways of Apoptosis Are Discovered 13 
Structural Approaches to New Therapies: 
A Jefferson Symposium 	 14 
Method to Isolate Stem Cells Is Found Here 	 18 
Learning Environment May Prevent Alzheimer's 21 
Jefferson Ranks in the Top Quarter of 
All Medical Schools in Training Grants 
	 21 
Book about the Art Collection is Now Available 25 
JAMA Study Proves That Jefferson Brings 
Family Physicians to Underserved Rural America 27 
Caring for the Ill and Wounded in Kosovo 
	 33 
Sally Johnson '76: Forensic Psychiatrist for 
Kaczynski and Other Extraordinary Cases 
	 37 
On the cover: Rick 
Hudes, M.D., Chief 
Resident in Radiation 
Oncology, and Maria 
Werner-Wasik, M.D., 
Assistant Professor, plan 
radiation treatment with 
a patient in a stereotactic 
body frame (see page 7). 
photo by Kelly & Massa 
On the back cover: 
ophthalmologists Marlon 
Maus '85 and Joseph 
Flanagan '63 and 
neurosurgeon Robert 
Rosenwasser, M.D.-
collaborators on a 
complex surgery 
(see page 33). 
Wills Eye Hosp photo 
Two products of Jefferson's Physician 
Shortage Area Program, James Devlin 
'85 (left) and Thane Turner '93 
(below), see patients in rural 
Pennsylvania. Article on pages 27-28. 
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Clinical Research 
Clinical cancer research at Jefferson is approaching the same level of excellence 
as our basic scientists. Walter Curran, M.D., Chair of Radiation Oncology at 
Jefferson, undertook the additional responsibility of Clinical Director of the 
Kimmel Cancer Center in 1997. He also serves as co-director of the lung cancer 
and brain tumor programs, and helped develop the Neurosensory Institute at 
Jefferson and Wills Eye Hospital which specializes in the use of the Gamma 
Knife and stereotactic radiosurgery, a super-precise radiation therapy. On the 
national level, Curran chairs the Radiation Therapy Oncology Group, a federally 
supported coalition of university departments which cooperate on clinical trials 
(the RTOG was in fact founded at Jefferson in the late 1960s by Dr. Simon 
Kramer). 
A newly formed Translational Research Committee at 
the Kimmel Cancer Center promotes collaboration 
between Jefferson's basic and clinical scientists, and 
ensures that they meet all the steps required in 
federally funded projects. Multidisciplinary teams 
cross department lines to focus on such areas as 
hematologic malignancies and lung, genitourinary, 
gastrointestinal, and head and neck cancers. Jefferson 
is a national leader for treatment of leukemia and 
colorectal cancer in particular. 
 
Capizzi 
 
Robert Capizzi, M.D., the Magee Chair of the 
Department of Medicine, has reorganized its Division 
of Medical Oncology and Medical Genetics to reflect 
increased interest in cancer genetics. Bruce Boman, 
M.D., Ph.D., an expert on hereditary cancer 
syndromes, particularly hereditary nonpolyposis colon 
cancer and familial adenomatous polyposis, was 
recruited to head this division. Services include family 
pedigree analysis, individual risk assessment, genetic 
counseling, and genetic testing. 
 
Boman 4i 
Bringing Cancer Knowledge from the 
A s we embark on the 21st century, Thomas Jefferson University is deploying 
'..imaginative research and treatment against a disease that strikes one of 
every four Americans. Jefferson's Kimmel Cancer Center is not a single building 
but an integration of components, including the Bluemle Life Sciences Building, 
Bodine Center for Cancer Treatment, and oncology programs within various 
departments. Scientists and clinicians are coordinated through an infrastructure 
that can promote common goals and centralize data management, expediting 
the transfer of research results to the bedside of the sick. 
Cancer research at Jefferson took a major step forward at the beginning of this 
decade with the recruitment of Carlo Croce, M.D., a world renowned geneticist. 
He oversees laboratories, primarily in the Bluemle Building, that encompass 
molecular biology, biochemistry, cell biology, immunology, structural biology, 
developmental biology, and genome mapping. 
Our efforts got a tremendous boost in 1995 when Sidney Kimmel, founder and 
chairman of the Jones Apparel Group, a leading women's clothing manufacturer, 
donated $10 million for research and for an endowed fund to continue 
Jefferson's fight against cancer. In appreciation, the university renamed its 
programs the Kimmel Cancer Institute and Kimmel Cancer Center. 
Also in 1995, Jefferson achieved recognition by the National Cancer Institute as 
a Clinical Cancer Center, one of five in Pennsylvania and approximately 60 
nationwide. 
The Kimmel Cancer Institute consistently merits grants approaching $50 
million annually, roughly three-quarters from the National Institutes of Health 
and the NCI, and the rest from nonfederal grants. This extramural funding 
makes cancer the largest research program at Jefferson. 
Unraveling Genetic Mechanisms 
The investigations at the Kimmel Cancer Institute (see pages 13-15) center 
around oncogenes which arise in the normal genome, sometimes as a result of 
certain viruses. Oncogenes up-regulate cell division. If they are mutated or 
translocated to another site, cells may divide out of control, causing cancer. 
A contributing factor can be mutations in tumor suppressor genes, which 
dampen the ability of cells to divide. If tumor suppressor genes mutate or are 
translocated, the body's normal controls against cancerous growth can be lost. 
With 10 million cells dividing in the normal human body every minute, and the 
external environment impacting upon the body, genetic mutations inevitably 
occur and are passed on. Humans also have genes which can repair DNA 
damage. But if these repair genes themselves become mutated, DNA errors may 
go uncorrected. This increases the chance that tumors will develop as the body 
is exposed to carcinogenic substances that alter DNA (see page 15, lower right). 
An early accomplishment by Jefferson's cancer researchers was the identification 
of a gene that plays a crucial role in promoting types of leukemia and 
lymphoma. TCL-1 is one of a group of genes implicated in the proliferation of 
T-cells and B-cells. Cancer occurs when the TLC-1 gene is moved out of its 
normal sequence on chromosome 14, and placed next to other elements known 
as enhancers which cause the gene to produce too much of its protein product. 
TCL-1 is the first gene to be implicated in low-grade leukemias such as T-cell 
prolymphocytic leukemia, T-cell chronic lymphocytic leukemia, and adult T-
cell leukemia. 
Recently, Jefferson investigators led by Dr. Croce and Professor Kay Huebner, 
Ph.D. discovered the FHIT gene, the second largest gene yet identified, which is 
involved in many common cancers (see page 13). Much work remains to be 
done before its mechanisms are clarified, but its significance is so great that the 
National Cancer Institute has called the discovery of the FHIT gene "the Rosetta 
Stone of cancer research." 
4 	 JEFFERSON Medical College Alumni Bulletin 	 December 1999 
Curran in the radiation facility 
Radiation therapists prepare a patient. 
Laboratory to the Patient 
Cancer Network and 
Oncology Group 
Jefferson is active in national coalitions conducting clinical trials, 
such as the Eastern Cooperative Oncology Group, the Gynecologic 
Oncologic Group, the Radiation Therapy Oncology Group, and the 
National Surgical Adjuvant Breast and Bowel Project. The number 
of cancer trials at Jefferson is increasing very rapidly. 
Many of the institutions linked together in the Jefferson Health 
System have formed the Jefferson Cancer Network (JCN) to 
enhance clinical and translational research by increasing the number 
of individuals enrolled in these trials. Patients at any JCN member 
can easily become enrolled in a wide array of trials, which offer 
patients the latest therapies as soon as they have been developed. 
Currently the network includes Jefferson, Atlantic City Medical 
Center, Bryn Mawr Hospital, duPont Hospital for Children, Albert 
Einstein Medical Center, Frankford Hospital, Grand View Hospital, 
Lankenau Hospital, Mercy Community Hospital, Mercy Fitzgerald 
Hospital, Mercy Hospital of Philadelphia, Methodist Hospital, 
Riddle Memorial Hospital, Underwood-Memorial Hospital, Wills 
Eye Hospital, and the Kimmel Cancer Center radiation oncology 
programs at Chestnut Hill and Lower Bucks Hospitals. 
With approximately 20,000 new cancer patients diagnosed within the 
Jefferson Cancer Network each year, Dr. Capizzi believes the Kimmel 
Center now has the critical mass needed to run conclusive clinical trials 
within the JCN itself. The Kimmel Center and the network provide 
sufficient infrastructure, technology, and numbers of patients to be a self-
contained trials group—the Jefferson Oncology Group—along the lines of 
the Eastern Cooperative Oncology Group. 
The JOG now has a common Institutional Review Board with approval 
authority over all trials involving its members. And the member institu-
tions are being coordinated so as to have a single signature contracting 
ability with pharmaceutical industry sponsors. 
Back on the university's Center City campus, it is likely that in the year 
2002, many of the scientists and clinicians of the Kimmel Cancer Center 
will move into a large new structure of their own. It would include 
outpatient facilities for ambulatory cancer patients, as well as research labs. 
The clinical side of the building would be laid out so as to encourage 
interaction between clinicians and investigators dealing with the same 
types of pathology. 
The new cancer building would mean a major expansion of total lab space, 
enabling Jefferson to recruit more investigators and obtain significantly 
more federal grant money than at present. Jefferson will become even more 
effective at better ways to predict, diagnose, and fight a devastating disease. 
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Increasing the Effectiveness of Radi( 
Nearly two thirds of people diagnosed with cancer today will receive radiation as part of their therapy. Incremental improvements in 
technology over the last century have culminated in what Chair of Radiation 
Oncology Walter J. Curran Jr., M.D. calls "revolutionary improvements over the 
last decade." At Jefferson's Kimmel Cancer Center, that revolution can be seen at 
the 50,000 square foot Bodine Center for Cancer Treatment, opened 12 years 
ago not only to offer the best, but also to ensure the continual development of 
new radiation therapy technologies. 
What has changed in recent years, said Curran, is that 
radiation oncologists and other cancer specialists have 
learned that the best cancer treatment often incorporates 
multiple specialties and modalities. "With trained oncology 
nurses, with pharmacists, with psychologists and social 
workers, the Bodine Center was one of the first centers in the 
Philadelphia area to recognize the need for multispecialty 
collaboration in the management of cancer patients," said 
Curran. "And we still serve as a model of that." Radiotherapy 
may be used in conjunction with surgery or chemotherapy to 
achieve more complete tumor elimination or to control 
metastasis, and in some cases it can also be used in place of 
surgery when the goal is to preserve organ function, such as 
in the case of cancers of the throat, larynx, esophagus, 
prostate, and breast. 
And even when a cure is not the goal, palliative radiotherapy may provide signif-
icant benefit to patients with cancers that are locally advanced or that have 
spread to the bone or the brain. Said Curran, "Probably about half of patients 
who have incurable cancer benefit from radiotherapy in terms of quality of life 
and pain control." 
The approach that Jefferson uses incorporates different technologies to provide 
image-based treatment planning and delivery. That typically includes techniques 
that immobilize the patient to the greatest degree possible; imaging modalities 
such as spiral CT scanning, which provides high resolution images; and 
planning tools that calculate the most effective way to deliver the right dose of 
ionizing radiation to the target while sparing normal tissues. 
Precision Targeting 
For the more than 200,000 men each year diagnosed with prostate cancer, all of 
the treatment options have risks. Surgery, while offering the potential of 
complete removal of the tumor, too often results in damage to the surrounding 
nerves, sometimes resulting in impotence and incontinence. Radiotherapy, in 
contrast, offers an increased likelihood of retaining sexual potency. Yet irradi-
ating prostate tumors buried deep in the pelvis places nearby sensitive 
structures such as the rectum and bladder at risk of radiation-induced damage. 
In order for radiation therapy to be an acceptable alternative in prostate cancer 
and many other forms of cancer, techniques have been developed that concen- 
trate the delivery of ionizing radiation to the tumor itself, while limiting radiation 
exposure of the surrounding tissue. 
The traditional approach to treatment planning, called conformal 3-D treatment, 
is to look at the cross-sectional CT image of the tumor and arrange the fields to 
miss healthy structures as much as possible, and then to irradiate the tumor from. 
a number of different directions. "That works rather well in concentrating the 
radiation in the target area and sparing the critical 
structures," said James M. Galvin, D.Sc., Professor and 
Director of the Medical Physics Division in the Department 
of Radiation Oncology. "We use our bag of tricks to get a 
good dose distribution." These tricks include various 
techniques that weight the fields differently and modify them 
with absorbers placed in the beam. 
An alternative to the traditional approach to treatment 
planning, called inverse planning, is now being used at 
Jefferson. Employing a delivery system called "Peacock," 
which was developed by Nomos Corporation of Sewickley, 
Pennsylvania, it allows the radiation oncologist to start with 
what is the ideal dose distribution and to work backward 
' from that point to determine the appropriate configuration of 
radiation delivery. "It's a total reversal of the approach," said 
Curran. "Normally we think of the fields and base the dose 
strictly on that. Here we think of the dose and then use the treatment planning 
technology to determine the delivery process that will give us that dose." 
The Peacock system delivers what is called intensity modulated radiation therapy 
(IMRT), using an approach known as "layered therapy," said Maria Werner-
Wasik, M.D., Assistant Professor of Radiation Oncology. A special crane moves 
across the treatment table, delivering many small radiation beams of varying 
intensity. This allows the physician to modify the delivery of radiation to 
conform to the shape of the tumor, even if it is an irregular shape, and to get 
uniform levels of radiation to tumors that vary in thickness and that have hard-
to-reach margins, while at the same time avoiding normal tissue. "It's the 
radiation oncologist's dream to be able to do this," said Werner-Wasik. By 
delivering radiation more precisely, Peacock allows the physician to deliver 
higher levels of radiation without harming normal tissue, thus increasing the 
likelihood of cure. 
In addition, physicians may be able to provide a second course of radiotherapy 
when necessary. "Peacock may allow us in some cases to treat tumors that recur 
after initial courses of radiation," said Werner-Wasik. 
The key to inverse planning is computation, according to Galvin. "You give the 
computer very detailed geometric information about the tumor you're trying to 
treat, and also about the critical body structures in the vicinity," he said. "Then 
you ask the computer to determine the ideal combination of beams and angles 
that will deliver a homogeneous dose of radiation to the various areas of the 
tumor regardless of its shape. And you give the computer the flexibility of 
varying the beam intensity at will." 
Curran 
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terapies 
The idea of inverse planning was developed in the 1980s and '90s, before there 
were convenient ways available for modulating the beam intensity point for 
point. "It was a technique in search of a technology to implement it," said 
Galvin. But in the early '90s, he and others introduced a new field-shaping 
device called the multi-leaf collimator, with which one can obtain any irregu-
larly shaped field using a computer to drive fingers in and out of the radiation 
beam. "It occurred to me that if you shaped different fields and then stacked 
them up, you could build up any intensity pattern. So with the introduction of 
the multi-leaf collimator, we now had a tool to modulate the intensity of the 
beam so we could deliver these inverse plans." 
This allowed radiation treatments to be shaped to irregular tumor volumes. "We 
could now shape the dose to a horseshoe-shaped tumor with a critical structure 
right in the center of it. We couldn't do that in the past." 
The problem with inverse planning is that the computer sometimes comes up 
with very elaborate solutions: elegant dose distributions that are difficult to 
deliver because of various compromises that were called for during the planning 
process. For example, when the tumor surrounds a critical structure, the 
delivery of sophisticated distributions of radiation sometimes requires 
sacrificing dose homogeneity. 
"So here at Jefferson we asked, well, if we're going to change the rules of 
treatment planning so dramatically, then why not go back to the traditional 
techniques and see how they perform under this new set of rules," said Galvin. 
This has led to the development of a new approach, dubbed forward planning as 
opposed to inverse planning. "We still have made it an intensity modulated 
delivery, it's just that whereas we had inverse planning coupled with IMRT, 
we're now using traditional techniques combined with IMRT. We have fields 
within fields and we still stack fields, but we use our past experience to say what 
those fields within fields should look like." While optimization of the plan is 
still left to the computer, said Galvin, "We give the computer 
more information going in, and tell the computer that we 
think that these fields are the ones it should be looking at. 
`Now, computer, you optimize it.' " 
Galvin explained that while inverse planning may be the 
wave of the future, the forward planning technique being 
developed at Jefferson is more suited to the technology that 
is currently available. Eventually, there may be a melding of 
the two approaches, he said. "The terminology will 
change—it will become simply computerized planning." 
Holding Still 
Galvin 
Another device that maximizes delivery of radiation to the 
target and not to surrounding tissue is the stereotactic body frame (see front 
cover photo), a piece of equipment with calibrating devices built into it that 
allow the precise localization of body structures in three dimensions during a 
CT or MRI scan. Historically, patients simply lay on a table while receiving 
radiation therapy. Then, plastic molds were introduced which kept people 
from rolling around during treatment. "But if you want to give high doses of 
radiation to critical areas in the body, we've concluded that you really need to 
have more rigid immobilization," said Curran. Jefferson was one of the first 
American sites to use the stereotactic body frame to immobilize patients during 
radiation therapy, and remains the only one in the Delaware Valley. 
The device looks barbaric, Curran remarks, resembling the kind of box a 
magician uses when he cuts a woman in half. The patient is placed in it prior 
to a CT scan. Images produced from this scan show the location of the tumor 
relative to fixed points in space provided by the calibrating device. Then, 
while the patient's positioning is maintained by the box, he is moved to the 
treatment area where radiation is delivered relative to those same fixed 
calibration points. 
The difficulty comes in transferring the patient from the CT scanner to the 
treatment area. Jefferson staff, however, have developed a unique transferring 
technique in which the patient can be moved off the CT scanner, down the 
hall, and into the treatment unit without being jostled. 
The Jefferson team uses a modified hospital gurney to facilitate this transfer. 
The gurney allows the staff to slide the patient smoothly off the CT couch, 
onto the transfer couch, and then onto the treatment table. Then, using marks 
on the patient and on the frame, the radiation fields are delivered to an exact 
position within the patient's body. 
"The importance of doing this is that we can now decrease the margins," 
Galvin explained. Margins refer to the area surrounding the tumor that may be 
irradiated during the treatment. Less precise localization of the tumor or more 
uncertainty about the patient's exact position relative to the images means that 
those margins must be increased in order to ensure 
adequate delivery of radiation to the tumor. "We're trying 
to minimize the size of the margins so that we are 
irradiating less of the healthy tissue, while still getting all 
of the tumor." 
New Approaches Make 
Radiotherapy Better 
For all of these new technologies, rigorous evaluation of 
the results is the key to ensuring progress in the search for 
better treatments. Jefferson patients benefit from partici-
pation in clinical trials of protocols developed all over the 
world, due to the university's involvement in federally 
funded cooperative oncology groups such as the Radiation 
Therapy Oncology Group, which Curran currently chairs. These clinical trials 
are essential for the continued evolution of therapies that will yield better 
outcomes and fewer side effects. 
7 	 JEFFERSON Medical College Alumni Bulletin 	 December 1999 
Werner-Wasik discusses a procedure, along with visiting fellow Marisa LoBao, M.D. 
Below: A radiation 
therapist prepares a 
patient for treatment. 
The mask protects 
areas of the face. 
For example, clinical trials recently resulted in 
preliminary FDA approval for an agent called 
amifostine, which protects against radiation-induced 
dry mouth, or xerostomia. Werner-Wasik with 
Robert Capizzi, M.D., the Magee 
Chair of the Department of 
Medicine, conducted this trial at 
Jefferson, and Werner-Wasik 
continues to see if this agent might 
be useful as a protectant against 
chemo- and radiation-induced 
esophagitis in lung cancer patients. 
Adam Dicker, M.D., Ph.D, Assistant 
Professor of Radiation Oncology, 
meanwhile has been working with a 
technique called brachytherapy, in 
which radioactive seeds are 
implanted into early stage prostate 
tumors. Dicker collaborates with 
Professor Frank M. Waterman, 
Ph.D. The idea behind 
brachytherapy is that higher doses 
of radiation can be delivered directly 
to the tumor, without affecting 
adjacent tissues. Long term studies 
of the effectiveness of brachytherapy 
are underway, as is research to 
improve the methodology. 
Dr. Dicker explains 
a set of CT scans. 
Right: Dr. Leeper 
biochemically quite different from those of radiation and 
drugs, Leeper explained. First, heat denaturizes proteins, 
in the same way that when you cook an egg, the protein in 
the white changes from a clear, slippery liquid to a white 
solid mass. By denaturing and changing the structure of 
proteins in cells, heat inhibits the repair of the tumor's 
damage from radiation and chemotherapeutic agents. 
Second, through other chemical and biochemical processes, heat makes the 
tumor's DNA more reactive with drugs and radiation, increasing the effectiveness 
of the drugs and radiation. And what makes the combination of heat and radio-
or chemotherapy even more desirable, is that the cells in tumors that are sensitive 
Adjuvant Therapies 
Many of the most promising developments in radiation oncology involve the use 
of adjunctive therapies that augment the standard treatment. One that has 
undergone extensive development at Jefferson is hyperthermia, or applying heat 
to the tumor. In the past two decades, said Dennis Leeper, Ph.D., Professor of 
Radiation Oncology, about 700 patients have received hyperthermia treatments 
at Jefferson. 
Hyperthermia increases the effectiveness of radiation therapy through two 
pathways: by killing cells directly and by making cells more sensitive to 
radiation-induced damage. The mechanisms of hyperthermia's effects are 
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RADIATION ONCOLOGY RESEARCH 
Women with Inherited Breast Cancer Gene 
Are at Greater Risk for Recurrence and New Tumors 
Li or many women under 40 with 
breast cancer, surgery to remove 
the lump and accompanying radiation 
seem a good way to get rid of the 
disease yet preserve the natural 
breast. But for women who carry a 
damaged version of BRCA1 or 
BRCA2, genes predisposing them to 
breast cancer, such treatment may not 
be enough. Researchers at Jefferson 
have found that such women have a 
greater risk of either relapsing or 
developing new tumors years later 
than those women who receive a 
lumpectomy and radiation therapy 
but don't carry one of these genes. 
As a result, says Bruce Turner, M.D., 
Ph.D., Assistant Professor of 
Radiation Oncology, who led the 
work, women and physicians may 
want to rethink their treatment 
options. "Our findings suggest that a 
woman who has a mutation in 
BRCA1 or BRCA2 who is treated with 
breast-conserving therapy not only 
has a high risk of local 
recurrence-40 percent according to 
our study—but also a high risk of 
developing cancer in the other breast 
as well," Dr. Turner says. 
"Our data imply that breast-
conserving therapy may not be the 
optimal treatment for breast cancer 
patients with BRCA1 or BRCA2 
mutations who want to reduce the 
risk of locally recurrent breast 
cancer." 
Dr. Turner and colleagues at Yale 
University and Myriad Genetics 
reported their findings in the October 
issue of the Journal of Clinical 
Oncology. 
Of 170,000 new breast cancer cases a 
year in U.S. women, about 10 percent 
of the women are under 40. Roughly 
10 to 15 percent of those women 
(2,000) carry an altered BRCA1 or 
BRCA2 gene, and about 70 to 80 
percent develop breast cancer. 
Dr. Turner and his 
coworkers looked at the 
frequency of alterations in 
BRCA1 and BRCA2 in 52 
breast cancer patients who, 
between 1973 and 1994, 
were treated with breast-
conserving lumpectomy 
and radiation, and who 
subsequently developed a recurrent 
cancer in the same breast. They 
compared these women to 52 other 
women who had localized breast 
cancer and were treated similarly but 
did not experience recurrent disease. 
The researchers found that eight, or 
15 percent, of the 52 women who had 
further breast cancer also carried a 
damaged BRCA1 or BRCA2 gene. In 
women 40 or under with recurrent 
breast cancer, six of 15, or 40 percent, 
had a damaged inherited BRCA1 or 
BRCA2 gene. In contrast, only one of 
15 women in the comparison group 
who did not have any recurrent 
cancers carried the bad gene. 
The scientists also found that it took 
longer—an average of about eight 
years—for women with an altered 
BRCA1 or BRCA2 gene to relapse 
than it did women without the 
damaged gene (slightly less than five 
years on average). They then carefully 
examined the tumors using molecular 
and histologic analysis, thinking these 
were old cancers that had returned. 
Instead, they found that some of the 
tumors were actually completely new 
breast cancers. The new cancers took 
an average of 8.5 years to develop. 
"If this study is validated with a larger 
prospective study, it may suggest that 
BRCA1 or BRCA2 testing may be 
reasonable to determine optimal 
breast cancer treatment—either 
breast-conserving therapy, 
or mastectomy for younger 
women with family 
histories of breast or 
ovarian cancer," Dr. 
Turner says. 
The study results may 
present women and their 
physicians with some 
difficult decisions regarding 
treatments. "If you told a woman with 
a damaged BRCA1 or BRCA2 gene 
that in nine years, 40 to 50 percent of 
patients like her are going to have a 
new breast cancer, and may need a 
mastectomy, then you'd have to 
present alternatives to her: would she 
prefer the lumpectomy and seven 
weeks of radiation, or would she 
rather have the mastectomy now and 
reduce the risk of recurrent disease?" 
One problem with recurring cancer is 
the threat that the disease may spread. 
While breast-conserving therapy may 
be curative for many women, some 
women who develop recurrent breast 
cancer also develop metastatic disease. 
Dr. Turner says that researchers now 
need to "look at patients with BRCA1 
or BRCA2 who have had a 
mastectomy and consider the 
frequency of chest-wall relapse and 
metastatic disease. 
"Presumably, removing 90 to 95 
percent of the breast cancer cells by 
mastectomy significantly reduces the 
future risk of breast cancer. But more 
definitive data is needed before we can 
justify this recommendation." it 
Radiation and Prostate, from page 9 
Prostate cancer tends to be a slow 
growing disease that men 
frequently die with, not from. 
Doctors often question whether 
surgery or radiation provide any 
real benefit for the older patient. 
Since 1990, the reported new cases 
of prostate cancer have more than 
tripled, from fewer than 100,000 
annually to more than 300,000, 
owing to better detection and 
greater public awareness. More 
than 60,000 men a year receive 
radiation therapy for localized 
disease. 
Dr. Valicenti and his Jefferson 
colleagues followed 149 men with 
localized cancer that had not 
spread beyond the prostate, who 
were considered high-risk for 
cancer recurrence after surgery. 
Fifty-two men were given radiation 
therapy three to six months after 
surgery; the others received no 
radiation. 
The scientists carefully matched 
the two groups according to factors 
that predict whether a cancer will 
return, settling on 72 patients in 36 
matched pairs. They then examined 
the patients every three to six 
months and tested their blood for 
prostate-specific antigen. Rising 
PSA indicates a returning cancer. 
After five years, 89 percent of the 
matched patients who had received 
radiation after surgery had no 
detectable PSA level, compared to 
only 55 percent of those who didn't 
get radiation. 
Valicenti and his colleagues hope 
to conduct a multisite national 
study to see if these results can be 
repeated with a larger group. 111. 
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Clinical Trial of Radiation and 
Thalidomide for Brain Tumors 
Researchers at Jefferson and 14 Cher sites around the country 
are enrolling patients into a National 
Cancer Institute sponsored clinical 
trial examining the effects of radiation 
and thalidomide in treating 
glioblastoma multiforme, a deadly 
brain cancer. The Phase Two trial, 
conducted by the nationwide clinical 
trial cooperative known as the 
Radiation Therapy Oncology Group, 
in collaboration with Celgene 
Corporation of Warren, New Jersey, 
aims to determine the drug's safety 
and effectiveness in extending 
patients' lives. The study, which will 
last into the year 2000, involves 
approximately 80 patients. 
Glioblastoma multiforme is the 
deadliest type of brain tumor. 
Although any of the brain's cells can 
turn malignant, glioblastoma 
multiforme, a tumor of the glial cells, 
is the most common and the most 
malignant. The tumor has a tendency 
to infiltrate surrounding tissue and is 
commonly associated with promoting 
blood vessel growth, bleeding, and 
tissue death. In the United States, the 
disease strikes approximately 9,000 
individuals, with a median survival 
time of about 12 months following 
diagnosis. 
"This combination treatment may be 
an important step in fighting a 
normally intractable illness that 
resists all other therapies," says 
Walter J. Curran Jr., M.D., Chair of 
the Radiation Therapy Oncology 
Group and Clinical Director of 
Jefferson's Kimmel Cancer Center. 
Curran points out that the RTOG 
study "is the first trial of its kind to 
look at radiation and thalidomide in 
treating any cancer." 
While surgery and radiation are the 
standard treatments for 
glioblastoma, their effects are 
usually temporary. Chemotherapy 
has marginal value, failing to reach 
areas in the brain to which the 
cancer has spread, says Curran, 
"which is why we have looked for 
alternatives." The study will include 
patients who have not previously 
undergone radiation therapy or 
chemotherapy. 
Thalidomide works by cutting off 
the blood supply to tumors. Tumor 
cells are frequently able to engineer 
new vessel growth, a process 
called angiogenesis (see graphic on 
page 9), which promotes the 
cancer's spread. Thalidomide 
inhibits a growth factor that tumor 
cells need in order to sprout new 
vessels. Thalidomide won't knock 
out the cancer cells, but may prevent 
them from spreading by cutting off 
nutrients which they need in order 
to multiply. Because the drug targets 
rapidly dividing cells, it is not 
expected to cut off the blood supply 
to most normal cells. 
If thalidomide works, it would be a 
complement to other strategies like 
surgery, chemotherapy, and 
radiation. "To control brain tumors 
effectively, we need a whole host of 
services," Curran explains. 
In the 1960s, thalidomide, originally 
intended to treat morning sickness, 
was banned around the world after 
causing thousands of babies to be 
born either without limbs or with 
flipper-like arms and legs. In recent 
years, however, the drug has been 
used to treat leprosy, cancer, AIDS, 
and other diseases. 
Adjuvant Therapies, from page 9 
to grow, they require new blood vessels to deliver oxygen and nutrients. By 
blocking the formation of new vessels, researchers believe they may be able to 
starve the tumor. Since angiogenesis inhibitors are cytostatic (preventing the 
growth of a tumor) rather than cytotoxic (killing the tumor), they will most 
likely be used in conjunction with chemotherapy or radiation therapy as a 
cancer treatment. 
One of the anti-angiogenesis agents being tested at Jefferson is thalidomide, 
the same drug that was widely given, with disastrous results, to pregnant 
women in the 1950s as a treatment for morning sickness. Thalidomide was 
withdrawn from the market when it was shown to cause severe birth defects. 
But in 1994, researchers demonstrated that the very properties that damaged 
the developing fetus, that is, inhibition of new vessel growth, could be used 
therapeutically to starve tissues such as tumors. An RTOG-sponsored clinical 
trial of thalidomide used in conjunction with radiotherapy as a treatment for 
brain glioma is now underway (see article at left), with Jefferson's Adam 
Dicker chairing the correlative studies section of the trial. 
icker explained that angiogenesis, as measured by the density of 
D 
 
microvessels (the MVD) in a given area, has been shown in many 
studies to correlate with tumor extent, aggressiveness, decreased survival, and 
lymph node metastases. A landmark paper in 1991 showed that in a study of 
women with breast cancer, all patients with microvessel counts over a certain 
threshold developed metastases. "This was the precedent for thinking, well, if 
there's increased angiogenesis in patients with more advanced disease, then 
presumably if you impact on the angiogenesis you might impact on the overall 
progression of the disease," said Dicker, who is collaborating on research with 
George Iliakis, Ph.D., Professor and Director of the Radiobiology Division. 
Another reason for the excitement about angiogenesis inhibitors is that 
preclinical data indicates little likelihood that tumors will develop resistance 
to these agents. "It takes a long time for these anti-angiogenesis agents to have 
an effect," Dicker notes, "but they have a very durable length of response." 
While Curran and the faculty in Radiation Oncology are proud of the basic, 
translational, and clinical research programs, Curran stresses that patient care 
is the top priority. To this end, the Kimmel Cancer Center recently celebrated 
the addition of two new partners, the radiation oncology center at Frankford 
Hospital, and the Jefferson radiation oncology center at Riddle Memorial 
Hospital in Delaware County. These facilities will help increase the number of 
newly referred patients seen through the Jefferson system to about 3,500 per 
year. Many of these patients are seen in multidisciplinary programs and 
benefit from the collaborations of researchers and clinicians in multiple 
specialties. 
"We're devoted to offering state of the art therapy while at the same time 
critically evaluating its potential benefit to patients," said Curran. "Just 
because it's new technology doesn't mean it's better." —Lisa J. Bain 
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Continuing Recognition for Jefferson's Specialists 
efferson's many experts on the 
causes and treatment of cancer 
continue to earn national recognition. 
A few highlights this past year: 
AACR-Pezcoller Award for 
Cancer Research 
Celebrated 
geneticist Carlo 
M. Croce, M.D., 
Director of 
Jefferson's 
Kimmel Cancer 
Center, has 
added the 
AACR-Pezcoller Award to his long list 
of achievements. The award is given 
by the American Association for 
Cancer Research to a scientist who 
has made a major discovery in cancer 
research. 
Dr. Croce, who also chairs Jefferson's 
Department of Microbiology and 
Immunology, has been a pioneer in 
understanding the genetic causes of 
cancer. The AACR noted that his 
"contributions have not only greatly 
extended our knowledge of cancer 
genetics, but they also constitute the 
basis for potential breakthroughs in 
gene therapy for human cancer." 
Among his accomplishments, Dr. 
Croce has explained the roles of 
chromosome alterations in human 
leukemias and lymphomas and 
identified several genes involved in 
blood cancers. A genetic profile of 
these genes is already being used in 
clinical settings to detect remaining 
disease in patients following 
treatment. 
More specifically, Croce described the 
molecular-genetic events that result 
in Burkitt's lymphoma, follicular 
lymphoma, and lymphomas in AIDS 
patients. He and his team have also 
isolated and named the ALL-1 gene, 
which is critical to the development 
of leukemias and lymphomas. Dr. 
Croce and Dr. Kay Huebner identified 
and cloned the tumor suppressor 
gene FHIT, which continues to yield 
vital information on the development 
of cancer (see article on facing page). 
A member of the National Academy 
of Sciences, Croce has won numerous 
honors including two Outstanding 
Investigator Awards from the 
National Cancer Institute, the 
General Motors Research Foundation 
Charles S. Mott Prize, the Pasarow 
Award, and the John Scott Award. 
Nation's Top Cancer Specialists 
According to Good Housekeeping 
Jefferson faculty Walter J. Curran Jr., 
M.D., Robert D. Fry, M.D., and 
Gordon Schwartz, M.D. are among 
the nation's top 318 cancer specialists 
for women, according to the 1999 
study by Good Housekeeping 
magazine. The guide lists the most 
respected experts for lung, breast, and 
colon disease. 
Good Housekeeping's editors made 
their selections based on nominations 
from nearly 300 department chairs 
and section chiefs at major medical 
centers around the United States. 
These physicians were asked to select 
"the specialists who provide the most 
expert treatment and who are the 
leading clinicians for lung, breast, and 
colon cancer in women." 
As Clinical Director of Jefferson's 
Kimmel Cancer Center, Dr. Curran 
oversees a range of the most advanced 
patient services in every specialty 
dealing with cancer. The Kimmel 
Center also acts as the point of entry 
for patients taking part in clinical 
trials conducted by Jefferson cancer 
specialists. Curran is also Chair of 
Radiation Oncology at Jefferson, and 
heads the Radiation Therapy 
Oncology Group, a consortium of 
more than 200 institutions in the U.S. 
and Canada aligned to conduct 
clinical trials. 
Robert Fry, 
M.D., 
Director of 
Colon and 
Rectal Surgery 
at Jefferson, 
has written 
extensively on 
the care of gastrointestinal disorders 
and cancers, especially those affecting 
the colon and rectum. He has collabo-
rated on more than 20 books and 
book chapters. Dr. Fry continues 
Jefferson's unparalleled success in 
managing colorectal cancer, and is 
also pursuing studies of the 
mechanism and treatment of inflam-
matory bowel disease. He is a 
Director of both the American Board 
of Colon and Rectal Surgery and the 
American Board of Surgery. 
Gordon F. Schwartz, M.D., Professor 
of Surgery at Jefferson, is a world-
renowned breast cancer surgeon. He 
serves on the editorial boards of 
Cancer, Seminars in Breast Disease, 
The Breast Journal, International 
Journal of the Breast, and Mammary 
Pathology, and is a member of the 
National Institutes of Health 
Reviewers Reserve. 
Dr. Schwartz also heads an interna-
tional group of breast cancer experts 
who meet at Jefferson each year to 
discuss the diagnosis and treatment of 
Ductal Carcinoma in Situ (DCIS), a 
controversial malignancy found in the 
breast. In recent years, the group 
designed a system for classifying 
DCIS, a first step toward improving 
treatment for this type of early breast 
cancer. DCIS currently represents 20 
to 25 percent of all breast cancers 
diagnosed. 
President of the 
Society of Breast Imaging 
Stephen Feig, M.D., 
Professor of 
Radiology at Jef-
ferson and Director 
of the Breast Imaging 
Center, is now the 
national President of 
the Society of Breast 
Imaging. A nationally recognized 
radiologist who specializes in breast 
cancer detection and diagnosis, Dr. 
Feig was one of the founding 
members of SBI in 1985. The society 
comprises more than 2,000 
radiologists. 
Feig is the author or coauthor of 
more than 300 papers and chapters 
and 15 books on breast imaging and 
breast cancer detection. His research 
has covered benefits, risks, and costs 
of screening mammography, 
especially for women ages 40 to 49, 
the technical quality of mammog-
raphy, and digital mammography. 
Dr. Feig is also a member of the 
American College of Radiology Breast 
Task Force and chairs the ACR's 
Mammography Accreditation 
Committee and the Ad Hoc 
Committee on Mammography 
Screening Guidelines. He holds 
leadership positions in the National 
Council on Radiation Protection and 
Measurements and the American 
Board of Radiology. He is Editor of 
the journal Seminars in Breast Disease 
and serves on the editorial board of 
Radiology.'  
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GENETIC EC ANISMS 
Molecular Pathways of Apoptosis 
T y detailing the precise molecular 
„ pathways of apoptosis, or 
programmed cell death, scientists at 
Jefferson are edging closer to new 
therapies against cancer, Alzheimer's 
disease, and Parkinson's disease. 
In the June 10 issue of the journal 
Nature, Emad Alnemri, Ph.D., 
Associate Professor of Microbiology 
and Immunology at Jefferson, in 
collaboration with Yigong Shi, Ph.D. 
of Princeton University, described the 
workings of caspase-9, an enzyme 
that is crucial to apoptosis. They have 
elucidated part of the cascade of 
cellular events leading to activation of 
this enzyme in apoptosis. 
"Labs across the country are trying to 
develop drugs that inhibit caspases, in 
order to fight neurodegenerative 
diseases and other diseases in which 
apoptosis is involved," points out Dr. 
Alnemri. Understanding the apoptotic 
pathway and each protein's role in the 
cell-to-cell communication process 
will open the way to developing 
drugs. 
Apoptosis is a fundamental biological 
process that is vital to cell differenti-
ation and normal 
development. In 
human embryos, 
for example, 
apoptosis creates 
fingers from 
mitt-like hands. 
It occurs during 
normal aging, 
and sometimes 
during 
irreversible cell 
injury from 
radiation or 
other poisons. 
Scientists believe 
that apoptosis 
gone awry underlies cancer, neurode-
generative diseases such as 
Alzheimer's and Parkinson's, and 
autoimmune diseases such as lupus. 
Apoptosis has received great attention 
in the popular press in recent years 
since scientists discovered that part of 
the reason cancer cells grow with 
abandon is that they lose the directive 
to die at a preset time. 
Alnemri is studying how various 
molecules affect the process, particu-
larly what triggers it to begin with. He 
focuses on caspases, a family of 14 
proteases (enzymes that degrade 
critical cellular proteins). Seven of 
these are known to be involved in 
apoptosis. Alnemri and his coworkers 
discovered many of the caspases 
themselves. 
In the Nature paper, the researchers 
concentrated on better understanding 
the chemical "recognition complex," 
or precise binding region, between 
caspase-9 and Apaf-1 (apoptotic 
protease activating factor one), a 
protein that helps regulate apoptosis. 
"They bind to each other—we 
published that in an earlier journal 
article—but no one knew how. The 
crystal structure of the binding 
complex was unclear," Alnemri 
explains. "We wanted to know which 
amino acids were involved." 
The scientists overexpressed and 
crystallized the actual pieces of Apaf-1 
and caspase-9 that bind to each other. 
Then they used x-ray crystallography 
to analyze the chemical structure of 
the recognition complex. They showed 
how mutation of even a single critical 
amino acid within the recognition 
complex can affect the binding 
between the two proteins. 
Dr. Alnemri contends that a key to 
halting the disease processes involved 
in degenerative diseases such as 
Alzheimer's may lie in this attachment. 
"If we find a molecule that can disrupt 
these two proteins from binding, it 
could be used in a drug. For example, 
a compound that could bind to the 
surface of the caspase might block the 
apoptotic pathway and prevent the 
process from occurring." 
Creating such drugs would involve 
developing peptides that mimic the 
chemical "recognition sequence" on 
the two crystal structures of caspase-9 
and Apaf-1, and then testing to see if 
they indeed disrupt apoptosis. It 
would be a first: no caspase-based 
drugs currently exist that block 
apoptosis in this manner. 
Further Evidence Links FHIT Damage with Breast Cancer 
cientists at Jefferson, working 
L./with the University Hospital of 
Iceland and the National Human 
Genome Research Institute in 
Bethesda, Maryland, have found 
further evidence linking damage to 
the tumor suppressor gene FHIT to 
the development of breast cancer. 
In a study of 92 Icelandic women, 
researchers led by Kay Huebner, 
Ph.D., Professor of Microbiology and 
Immunology at Jefferson, showed 
reduced levels of Fhit, the protein for 
which FHIT encodes, both in women 
with sporadic breast cancer and in 
those with hereditary breast cancer 
who carry a BRCA2 mutation, a gene 
predisposing them to develop the 
disease. Among the 58 sporadic and 
34 BRCA2-associated breast cancers, 
Dr. Huebner's team reported a "signif-
icant association" between damage to 
the FHIT gene at its most fragile area 
and a reduced expression of the Fhit 
protein. 
"Genetic alterations at this most 
common fragile site in the FHIT gene 
lead to reduced Fhit protein expression 
in sporadic cancers and in a much 
larger fraction of BRCA2-associated 
familial cancer," Dr. Huebner explains. 
"This is consistent with the idea that 
loss of BRCA2 function affects the 
stability of the FHIT site." 
continued on page 15 
Huebner 
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UNRAVELING MOLECULAR MECHANI 
Structural Approaches to New Therapies: 
Jefferson Symposium Attracts Some of the Foremost Experts 
diverse group of scientists 
eeting this past spring at 
Jefferson demonstrated the power and 
the potential of structural biology and 
chemistry in the search for novel 
therapies. The symposium, 
"Structural Chemistry and Biology of 
Cancer and Immune Diseases: From 
Basic Research to the Clinic," was 
organized by Ziwei Huang, Ph.D., 
Director of Rational Drug Design at 
Jefferson's Kimmel Cancer Institute. 
It attracted scientists from both 
academia and industry and from 
disciplines ranging across the 
spectrum of basic and clinical science. 
What all these scientists shared was a 
research approach that exploits 
knowledge about the molecular 
structure of various proteins: using 
these structures as templates in the 
design of molecules that interfere 
with or regulate the function of 
physiological systems. But these 
scientists' specific tactics and targets 
varied. Targets include cancer cells 
and viruses as well as the molecules 
involved in cell cycle regulation, 
immunomodulation, and 
angiogenesis. 
Some of the new therapies developed 
using this structural approach have 
already made it to the clinic, and 
many more are in the pipeline. 
Structural Variations Yield 
Different Activity Profiles 
One approach with implications in 
the fight against both cancer and viral 
diseases such as HIV involves the use 
of molecules that are structurally 
similar to the nucleotides normally 
used as building blocks in DNA 
synthesis. Dr. Yung-Chi Cheng, 
Professor of Pharmacology at Yale 
University, described a new class of 
these agents called L-nucleoside 
analogs, which take advantage of the 
unique features of DNA synthesis in 
cancer cells or virally infected cells. 
Currently there are several deoxynu-
cleoside analogs, such as AZT 
(zidovudine) and ddC (zalatibine), 
which are used clinically against HIV. 
When these compounds get into the 
cells of individuals infected with HIV, 
they are chemically altered and then 
incorporated preferentially into the 
viral DNA, where they prevent 
interaction with the viral enzyme 
reverse transcriptase so that the DNA 
chain can no longer elongate, and 
DNA synthesis stops. While these 
compounds do interfere with viral 
reproduction without causing bone 
marrow suppression (an acute toxic 
reaction associated with other anti-
viral agents), prolonged clinical use of 
these drugs has resulted in a delayed 
type of toxicity affecting various 
tissues and organ systems. 
Dr. Cheng's lab was interested in 
studying the underlying mechanism 
of the delayed toxicity. They 
discovered that it was due to a 
depletion of mitochondrial rather 
than nuclear DNA, and that even 
slight differences in the structure of 
the deoxynucleosides resulted in 
different toxicity profiles. At the same 
time, his lab was searching for 
compounds that would be effective 
against the hepatitis B virus (HBV). 
Dr. Cheng reasoned that since HBV 
uses a reverse transcriptase similar to 
HIV, the nucleotide analogs effective 
against HIV might also work against 
HBV. Indeed, they found that anti-
HIV compounds such as ddC were 
effective against HBV. They went on 
to synthesize compounds with a 
number of structural variations and 
found that different modifications 
yielded compounds effective against 
different viruses as well as 
compounds that interfered with the 
reproduction of some cancer cells. 
Further, the knowledge that they are 
gaining about the effect of these 
compounds on viral infections has 
yielded new insight about the role of 
molecular structure in the 
phenomena of drug resistance and 
synergism when combinations of 
drugs are used. 
Modulating Immunity 
Structurally 
While Dr. Cheng searched specifically 
for compounds that might interfere 
with the virus itself, other scientists 
have sought means of stimulating the 
immune system to defend more 
effectively against viral diseases and 
cancer. Dr. Harvey Cantor, Professor 
of Pathology at Harvard Medical 
School, discussed an anti-cancer 
vaccine strategy that seeks to 
modulate the cytokines that mediate 
protective immune responses. 
According to Dr. Cantor, the current 
paradigm for cytokine interaction is 
that interleukin-12 (IL-12), produced 
by macrophages and dendritic cells, 
imprints a Type I or cell mediated 
immune response. Another cytokine, 
IL-10, diminishes the Type I response 
while encouraging the humoral or 
allergic (Type II) response. Dr. 
Cantor's lab has been studying a gene 
called Eta-1 (for Early T-cell 
Activation), which is the major newly 
synthesized RNA in activated T-cells. 
"We think that the expression of Eta-
1 is an essential early link between 
T-cell activation on the one hand and 
the drive towards Type I immunity on 
the other; and that the engagement of 
its two receptors, leading to 
diminished IL-10 and increased IL-
12, is the key to its action," he said. 
According to Dr. Cantor, the two 
effects of Eta-1 are mediated by 
distinct receptors that interact with 
different portions of the Eta-1 
molecule. When one end of the 
molecule, the N-terminus, is 
phosphorylated, it engages one type 
of receptor and leads to IL-12 up-
regulation. The other end of the 
molecule, the C-terminus, engages a 
different receptor and down-regulates 
IL-10. 
By understanding the role that 
chemical structure plays in these 
regulatory mechanisms, Cantor hopes 
to be able to engineer structural 
modifications that will allow manipu-
lation of this part of the immune 
response. "This kind of observation 
also opens possibilities for using this 
cytokine or engineered versions of 
these cytokines in vaccines," he said. 
Interfering with Receptor 
Binding and Activation 
Dr. Elias Lolis, Associate Professor of 
Pharmacology at Yale, discussed a 
subset of cytokines called 
chemokines, chemotactic cytokines 
that mediate inflammation. 
Chemokines comprise the largest 
family of cytokines, with over 40 
distinct types identified. They play a 
role in immune defense, 
hematopoiesis, and angiogenesis. 
Chemokines interact with receptors 
expressed on subgroups of 
leukocytes, white blood cells that 
mediate the inflammatory response. 
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Receptor activation initiates a cascade 
of biochemical reactions that regulate 
intracellular processes. Chemokine 
receptors also may bind to pathogens 
and this binding may be a 
requirement for the organism to enter 
the cell. The understanding of this 
function for chemokine receptors 
recently led several groups of 
scientists to the discovery that some 
individuals who appear resistant to 
HIV infection in fact have a mutation 
in the chemokine receptor dubbed 
CCR5. This mutation prevents the 
CCR5 molecule from reaching the 
cell surface; as a result HIV cannot 
bind and gain entry to the cell. Since 
these individuals appear to be 
otherwise healthy, CCR5 may be a 
safe target for inhibition. 
Dr. Lolis has been working to define, 
at a structural and chemical level, the 
process of chemokine binding and 
receptor activation with the goal of 
designing safe and effective 
inhibitors. Because the chemokines 
are important in so many physiologic 
systems, compounds that modulate 
chemokine activity could have 
applications in treating a broad range 
of illnesses. 
Structural biologists and chemists 
have targeted numerous other 
receptor/ligand binding interactions 
with the goal of manipulating the cell 
cycle. Wayne Hendrickson, Professor 
of Biochemistry and Molecular 
Biology at Columbia, discussed one of 
the most ubiquitous of these 
processes: signalling by cellular 
growth factors through receptor 
tyrosine kinases. Through different 
but related pathways, protein tyrosine 
kinases mediate the process by which 
a variety of growth factors and 
hormones exert their effects. "Many 
different pathways work through 
tyrosine kinases," Hendrickson said. 
"What's emerging is a nicely unified 
set of principles by which these 
actions occur." 
Protein kinases transmit signals along 
various pathways by transferring 
phosphate groups to other proteins. 
The structural changes that result 
from phosphorylation may result in a 
gain or loss of function in that 
protein. One important type of 
protein kinases is called the cyclin-
dependent kinases (CDKs). 
"You can think of the CDKs as 
engines that drive the cell cycle, 
whose regulation is frequently altered 
in neoplasia," said Dr. Edward A. 
Sausville of the National Cancer 
Institute. Consequently, he said, 
"They represent a potential target for 
both refining prognosis and defining 
new therapies." In fact, the NCI is 
currently involved in Phase I clinical 
trials of a direct CDK antagonist 
called flavopiridol. According to 
Sausville, flavopiridol appears to act 
at two different phases of the cell 
cycle. In addition, different types of 
tumors are differentially sensitive to 
flavopiridol-induced apoptosis 
(programmed cell death), indicating 
that the full story of how the drug 
works may be more complicated than 
CDK antagonism—as well as more 
revealing about the function of the 
CDKs. 
These are only a sampling of the 
approaches discussed at the Jefferson 
symposium, yet representative of the 
types of strategies structural 
biologists and chemists are using to 
understand disease processes and 
develop new therapies. Combined 
with techniques developed by 
FHIT, from page 13 
An improved understanding of the 
FHIT gene may lead to the identifi-
cation of individuals predisposed to 
some of the most common human 
cancers, and the development of new 
drugs that may arrest their growth. 
In 1996, Dr. Huebner and Carlo M. 
Croce, M.D., Director of Jefferson's 
Kimmel Cancer Center, identified and 
characterized FHIT. It is located in 
the human genome's most fragile 
area, on human chromosome three in 
a region known as 3p14.2. The area 
has an exceptionally high number of 
DNA gaps, breaks, and rearrange-
ments. The researchers believe that 
FHIT's fragility is involved in the start 
or progression of such cancers as 
esophageal, gastric, kidney, breast, 
and lung. 
"We knew that this region on 
chromosome three was prone to 
damage by carcinogens," Dr. Huebner 
says, "though we don't know what 
those carcinogens are, or what causes 
the genetic breakage. In sporadic 
tumors, the FHIT site is damaged, 
and the BRCA2 gene, and maybe 
BRCA1, are active and can probably 
repair the damage. 
"But when BRCA2 is missing, many 
cells cannot repair the damage 
without BRCA2's repair mechanism; 
and this contributes to cancer growth. 
Perhaps part of what BRCA2 does is 
Jefferson's Dr. Huang for computer 
design of molecules, these structural 
approaches promise significant 
advances in the battle against cancer, 
AIDS, and many other diseases of 
our time. —Lisa J. Bain 
to protect the integrity of the cell, 
especially in fragile regions. BRCA2 
function appears to be important to 
the stability of the FHIT site. 
"One of the reasons this is exciting is 
because of what it tells us about 
repair genes in general in cancer," 
Professor Huebner says. It is possible 
that FHIT and the fragile 
chromosome three site are also more 
likely to be severely damaged in 
tumors of people with MSH2 and 
MLH1, such as in colorectal cancers. 
Previous studies of patients from 
Iceland showed a loss of DNA that 
was significantly higher in this region 
in familial compared to sporadic 
tumors. In this study, tumors in more 
than 30 women with hereditary breast 
cancer showed variously lower 
amounts of Fhit. All of the women 
had a defective BRCA2 gene predis-
posing them to cancer. Dr. Huebner's 
researchers think that the frequency 
of women with a damaged FHIT in 
cancer cells could indicate that those 
with a missing BRCA2 can't repair 
DNA damage when it occurs in FHIT. 
"Currently, we are looking at other 
fragile sites in BRCA2 and BRCA1 
cases and in MLH1 and MSH2-
associated tumors, which are deficient 
in DNA repair mechanisms. It would 
be very helpful to know which genes 
are affected when you lose BRCA2 
repair function." 
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Turner 
Proof that Access to New Methods 
of Prevention Depends on 
Where Patients Receive Care 
ow well are medical advances 
translated into community practice? 
In the case of HIV-infected pregnant 
women, where they get their care may 
make a big difference. 
In 1994, researchers across the country 
were thrilled when they found that the 
anti-HIV drug AZT, taken during the 
second and third trimester, could reduce 
mother-newborn transmission of AIDS by 
as much as two-thirds. Along with 
national educational efforts, New York 
State mounted an information campaign, 
sending letters to physicians and other 
health care specialists, even conducting 
marketing campaigns to high-risk groups. 
Researchers at Jefferson asked, how 
quickly would community practitioners 
(who are statistically slow to change their 
approaches) adopt new practices to treat 
poor, pregnant, HIV-infected patients? 
Which patients would benefit from the 
new knowledge? 
While community physicians in New 
York State responded rapidly to the 
findings, patients in certain health care 
settings benefited much more than 
others. The researchers found that 
women were more likely to receive 
antiretroviral treatment during pregnancy 
if they were (1) being treated at a medical 
center that performed HIV clinical trials, 
(2) were being treated at sites paid by 
the state to deliver a range of specific 
HIV-focused services to persons 
enrolled on Medicaid, (3) were 
receiving prenatal care, or (4) were in a 
methadone program. 
"Where women get their medical care 
makes a big difference in whether they 
get access to important advances," says 
Barbara J. Turner, M.D., Professor of 
Medicine and Director of Health Care 
Research at Jefferson's Center for 
Research in Medical Education and 
Health Care, who led the study. The 
findings were reported June 15 in the 
Annals of Internal Medicine. 
The study involved the results of the 
Pediatric AIDS Clinical Trials Group 
protocol 076, arguably the biggest 
advance in HIV prevention yet. The trial 
was halted early and its results showed 
AIDS transmission could be substan-
tially reduced during delivery by giving 
AZT to the pregnant women during the 
last two trimesters of pregnancy, and to 
the baby during the first six months of 
life. But because the findings were not 
published for nine months, Dr. Turner 
explains, "the news got out via news 
releases, educational programs for lay 
persons and professionals, and direct 
mailings to doctors" (rather than via a 
definitive peer reviewed journal article). 
In the Annals paper, Dr. Turner and her 
colleagues examined three time periods: 
January 1993 until the announcement; 
nine months from announcement until 
formal journal publication; and after 
formal publication until September 1996. 
They looked at the treatment records of 
2,607 HIV-infected women who delivered 
live children. They found that after 
adjusting for patient and health care 
delivery factors, these Medicaid enrolled 
women had a 21 percent increase per 
month in their likelihood of receiving 
antiretroviral therapy during pregnancy. 
After the formal journal publication, the 
rate increased more slowly. 
"But we found that certain women were 
more likely to be treated," says Dr. Turner, 
such as those already receiving care at 
centers of excellence. New York State has 
identified centers and physicians who 
contract to deliver a range of HIV-related 
services (such as nutritional care) and to 
Dr. Turner sees several lessons 
from her team's study, which was 
funded by the National Institute on 
Drug Abuse, including the possible 
need for a "direct marketing program 
after a dramatic finding such as the 067 
trial. The adoption of medical advances 
in private practice has been statistically 
far slower than in academic medical 
centers." 
Currently, Dr. Turner and her 
coworkers are following the data on the 
women through 1998 to see which 
groups of women received antiretroviral 
therapy up to two years after they gave 
birth. 
In recognition of her expertise on health 
care practices, Dr. Turner has recently 
been appointed Medical Editor of 
Hippocrates, a journal for primary care 
physicians published by the 
Massachusetts Medical Society 
(publisher of the New England Journal of 
Medicine) 
treat special medical complica-
tions. "If a woman was treated at 
one of these sites, she was more 
likely to be treated with antiretro-
viral therapy," Turner says. 
"Similarly, if a woman was 
treated at a site that had earlier 
been part of the 076 trial, she was 
50 to 70 percent more likely to 
receive antiretroviral therapy. 
That argues for care from medical 
centers that offer clinical trials." 
0.1 
A Mechanism to Control Red Blood Cell and Platelet Production 
esearchers at Jefferson have 
uncovered a potential switch that 
helps control the manufacture of red 
blood cells and blood-clotting platelets. 
By better understanding how the body 
keeps tight reins on this process, the 
scientists hope to someday therapeuti-
cally control blood cell production. 
For our tissues to have the oxygen they 
crave, we need to have enough 
circulating red blood cells. Athletes may 
artificially boost the number of red 
blood cells (as many Olympic officials 
know) using a hormone, erythro-
poietin, which helps immature red 
blood cells to mature. But too many 
cells can cause sluggish circulation and 
stroke. 
Controlling the amount of the hormone 
is one way of regulating red blood cell 
production. But there's another way, 
called "negative regulation," which 
involves blocking the growth and differ-
entiation of red cell precursors. By 
activating the cell's own programmed 
suicide process, apoptosis, researchers 
can halt the excessive production of red 
blood cells. 
Cesare Peschle, M.D., Professor of 
Microbiology and Immunology at 
Jefferson, Ruggero De Maria, M.D., and 
their coworkers at Jefferson and the 
Istituto Superiore di Sanita in Rome, 
found evidence that by activating so-
called "death receptors" on the surface 
of immature red blood cells, an 
important protein called GATA-1 can 
be turned off. GATA-1 is crucial to the 
development of immature blood cells. 
The team reported its work September 
30 in the journal Nature. 
continued on page 18 
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Despite the Best Available Drugs, HIV Is Indeed Active in the Bloodstream 
rrhe best AIDS drugs are still not good 
enough. Scientists at Jefferson have 
found evidence for the first time of 
actively replicating HIV in the 
bloodstream of patients taking the most 
powerful anti-HIV drugs available. 
Scientists knew that the combination of 
drugs known as HAART, highly active 
antiretroviral therapy, did not eradicate 
the AIDS virus, despite the fact that the 
virus could not be detected by conven-
tional means in the patient's blood. But 
they thought that the drugs had at least 
arrested the virus from replicating. No 
one had been able to find active virus in 
the blood of patients on the drugs. 
Until now. Roger J. Pomerantz, M.D., 
Chief of Infectious Diseases, and his 
coworkers examined 22 HIV-infected 
patients taking HAART. Using ultrasen-
sitive molecular techniques, he and his 
team found evidence of active virus in 
the blood plasma of every patient. Their 
results appear November 3 in the Journal 
of the American Medical Association. 
"We are the first to show that in such 
patients, the virus spills out of the 
immune cells it normally infects, and 
spills into the blood, possibly infecting 
other cells," says Pomerantz. 
"We need to be able to stop replication 
of the virus before we think about 
eradication." Dr. Pomerantz also calls for 
better detection methods, because "in the 
era of HAART, we're often dealing with 
low levels of virus." 
Pomerantz's JAMA article looked at 
people taking HAART, a combination 
therapy of protease and reverse 
transcriptase inhibitors, who had no 
detectable virus in their blood by the best 
available clinical assays. All patients had 
fewer than 50 copies of virus per milliliter 
of blood plasma. Using extremely 
sensitive techniques, Pomerantz's team 
found active virus in every person. 
A recent study of patients on HAART and 
interleukin-2 showed that when the drugs 
were halted, all patients' viruses returned 
to earlier levels, and they developed 
symptoms. 
Pomerantz's group also found active virus 
in the seminal fluid of 10 patients. They 
previously reported that the AIDS virus is 
still present in a potentially infectious, 
latent form in the semen of infected men 
taking HAART, even when no measurable 
virus can be found in the blood. "Now 
we're dealing with two things in these 
patients: residual HIV that's replicating, 
and residual HIV that's latent," he says. 
He's using these new findings in ongoing 
clinical studies to attempt to eradicate 
HIV in certain patients. 
Drug Profiles and Tailor-made Therapies Are Needed 
esearchers may be able to sidestep 
IV resistance to drugs by creating 
drug resistance profiles of patients 
before they begin treatment, writes 
Roger J. Pomerantz, M.D. in the 
September 22 issue of the Journal of the 
American Medical Association. By 
knowing which drugs a patient is 
resistant to, doctors may someday 
custom-design therapies against HIV, 
and thereby improve treatment. 
But certain obstacles still stand in the 
way, explains Dr. Pomerantz, who is 
Chief of Infectious Diseases at Jeff. 
More research is needed to understand 
drug resistance, and scientists must 
come to agreement on when a patient's 
viral resistance means something 
clinically. 
In the JAMA editorial, Pomerantz 
comments on two studies published in 
that issue that focus on groups of 
patients in quite different geographic 
locations. Some of the patients in both 
studies were resistant to a commonly 
prescribed and frequently effective 
cocktail of drugs known as highly active 
antiretroviral therapy (HAART). 
The researchers in both studies defined 
drug resistance differently, leading to 
different opinions about the degree of 
resistance found in the study popula-
tions. 
"Two things need to be done," 
Pomerantz says. "We need to 
understand how large the problem of 
primary drug resistance is, and part of 
that means watching different 
geographic areas to gauge how much 
multidrug resistance is developing. 
Then, for each drug, we have to find a 
way to agree on what the degree of 
clinically relevant resistance is. 
"Clinically relevant drug resistance will 
differ for each drug, just as it is different 
for penicillin and vancomycin for 
bacteria," he says. "We have to find out 
if a threefold increase in viral resistance 
means something about the effectiveness 
of one drug compared to what it means 
for another," he says. 
In the JAMA editorial, he calls for 
medical officials to be more alert to 
multidrug resistance. "If you give a 
patient a cocktail of drugs the first time 
and they don't respond, and you can't 
find it's from noncompliance, you have 
to think they may have primary 
resistance." 
Eventually, all patients may need to be 
profiled for both their virus's genetic 
makeup and their disease status, "just as 
we do for pneumococcus and tubercu-
losis before treatment," he says. 
"What does it mean when you have X 
resistance to AZT, and at the same time, 
what does it mean regarding a different 
drug, such as a certain protease 
inhibitor? It would be desirable to tell 
patients you are this much resistant to 
drug X and that much resistant to drug 
Y, and not to these others." 
Dr. Pomerantz sees the day when each 
anti-HIV drug will actually have a 
profile of standard viral resistance. "You 
could say to a patient, 'This is your 
virus, these are the drugs it's resistant 
to, and this is what we'll use against it.'" 
Tailor-made, individually designed 
therapies may become more common. 
Dr. Pomerantz compares the current 
AIDS drug resistance situation to the 
early days of bacteriology at the turn of 
the century. Doctors watched how new 
drugs affected different patients, and 
devised new definitions of clinically 
relevant conditions. "HIV is evolving 
differently in different areas of the 
country," he says. "Defining resistance 
for each drug is exactly what we did 
earlier in the century for bacterial 
infections such as tuberculosis, when 
people were developing resistance." 
Of course, detailing the precise viral 
genetic makeup of each HIV-infected 
individual would cause treatment costs 
to rise significantly. This would be a 
particular problem for Third World 
nations struggling against the onslaught 
of AIDS. Millions are infected, and 
many lack primary medical care. No 
one knows the scope of drug resistance 
there, Dr. Pomerantz points out, 
because in many cases, patients do not 
receive adequate medical attention, let 
alone consistent therapy. 
INVESTIGATIONS 
Jefferson Discovery of How to Isolate Stem Cells 
Could Lead to Lab Production of Blood Cells 
Sdentists at Jefferson have found a way to isolate hematopoietic stem 
cells. "This has been the elusive Holy 
Grail of hematology and 
immunology," says Cesare Peschle, 
M.D., Professor of Microbiology and 
Immunology. "Now we have found it, 
by identifying the first specific and 
functional stem cell marker." 
This could lead to laboratory 
production of all types of blood cells, 
for transfusions and for innovative 
approaches to bone marrow 
transplants and gene therapy. 
Dr. Peschle (who is also Chair of 
Hematology-oncology at Istituto 
Superiore di Sanita in Rome) and his 
coworkers at Jefferson's Kimmel 
Cancer Center, and in Italy, Germany, 
and at the University of Nevada 
reported their work September 3 in the 
journal Science. 
Hematopoietic stem cells, created by 
bone marrow, have two unique 
abilities: to develop into any kind of 
blood cell and to self-renew by 
generating new daughter stem cells. 
Yet they are very rare, making up only 
one in 100,000 marrow cells. They 
have been notoriously difficult to 
distinguish from the blood's other 
progenitor cells, which are further 
along in the differentiation process. 
"We have found a marker—KDR-
which seems to be specific for the 
hematopoietic stem cell as compared 
to other primitive hematopoietic 
cells," Dr. Peschle says. 
"The use of the stem cell is very 
important and broad. Having purified 
it, we can characterize it at a 
functional, phenotypic, and molecular 
level." Scientists can also learn to 
manipulate the cell in the laboratory, 
he says, and "to induce the stem cell 
to do in the laboratory what it does in 
the body: self-renew and differentiate 
to generate a huge number of red 
blood cells, white blood cells, and 
platelets." Scientists then can generate 
in the lab the circulating blood cells 
required for blood transfusions, which 
currently are obtained by transfusions 
from normal donors. 
For years, researchers have had 
tremendous difficulty distinguishing 
between two types of precursor blood 
cells: hematopoietic progenitor and 
stem cells. Progenitor cells are 
immature cells that can differentiate 
into red blood cells, white blood cells, 
and platelets. They are used to restore 
patients' blood and immune systems 
after high dose chemotherapy or 
radiation for cancer. Stem cells are 
earlier cells which have the unique 
capacity to self-perpetuate. They 
generate progenitor cells and blood 
cells throughout life. Progenitors have 
no self-renewal capacity—they only 
give rise to more differentiated 
precursor cells. 
Scientists can isolate undifferentiated 
progenitor cells using a marker on the 
cell known as CD34. This method-
ology was pioneered by Dr. Peschle 
and coworkers in a report in Science 
in 1990. But identifying hematopoietic 
stem cells has been more difficult, 
Peschle explains. Hematopoietic 
progenitor cells are rare: between 0.5 
and one percent of bone marrow cells 
are progenitors carrying CD34. Yet 
stem cells are even less frequent, 
perhaps 0.1 percent of CD34 cells, or 
one stem cell in 100,000 marrow cells. 
The problem was that there was no 
specific marker on the cell surface of 
stem cells comparable to CD34 on 
progenitor cells. "Once you have a 
marker protein for hematopoietic 
stem cells," Dr. Peschle explains, 
"you can theoretically raise antibodies 
against the marker, and then you can 
separate stem cells from other cell 
populations." 
They focused on KDR, a protein that 
functions as a receptor for the 
vascular endothelial growth factor. 
KDR is expressed on endothelial cells. 
The scientists found that it is also 
expressed at low levels on CD34-
positive progenitor cells. In 
embryonic life, primitive 
hematopoietic cells are made in 
close contact with KDR-positive 
endothelial cells. They argued that 
KDR may represent a marker for 
hematopoietic stem cells after birth. 
They found an antibody that 
recognized the KDR receptor and 
which could isolate the KDR-
expressing cells from the other 
progenitors in the CD34-positive 
progenitor population. Those cells 
with KDR comprised the 
hematopoietic stem cells but no 
progenitor cells. 
Now Dr. Peschle and his coworkers 
have precisely evaluated the 
capability of KDR-positive stem cells 
to repopulate the bone marrow with 
blood cells after marrow transplants 
in animals. They can also determine 
the exact frequency of stem cells in 
the KDR-positive population. 
The ability to eventually harness the 
hematopoietic stem cell in both the 
laboratory and clinic should help 
alleviate blood shortages for transfu-
sions, and permit innovative 
approaches to marrow 
transplants. 
Red Blood Cells, from page 16 
The team found that turning on 
immature red blood cell death receptors 
triggers caspases, a family of 14 cysteine 
enzymes that degrade critical cellular 
proteins, such as GATA-1. This 
culminates in a reversible blockade of 
growth and differentiation of red cell 
precursors, which may lead to cell 
death. Their article in Nature details 
part of the intricate cascade of cellular 
events leading to activation of these 
enzymes in the blockade of red blood 
cell development. 
Apoptosis is a fundamental biological 
process that is vital to cell differenti-
ation and normal development. In 
human embryos, for example, apoptosis 
creates fingers from mitt-like hands. It 
occurs during normal aging and 
sometimes during irreversible cell injury 
from radiation and other poisons. 
Scientists believe apoptosis gone awry 
underlies neurodegenerative diseases 
such as Alzheimer's and Parkinson's 
diseases, autoimmune diseases such as 
lupus, and cancer. 
Apoptosis received a great deal of 
attention in recent years when scientists 
discovered that part of the reason cancer 
cells grow with abandon is that they 
lose the ability to die at a preset time. 
The Jefferson group's work represents a 
"new frontier" in understanding 
apoptosis, Dr. Peschle says. He explains 
that "mild stimulation of death 
receptors and caspases induces a 
reversible inhibition of red cell 
development rather than apoptosis." 
This provides a key mechanism in fine 
tuning cell growth and differentiation. 
Such a novel mechanism may be of 
general significance, he says, and apply 
to diverse cell types in addition to red 
blood cells and platelets. Failures in the 
mechanism may lead to either abnormal 
cell growth inhibition or excessive cell 
proliferation, such as occurs in some 
anemias and leukemias. 
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Glucosidase Inhibitors May Be Effective against Hepatitis 
Desearchers at Jefferson may have 
n.found a promising drug against 
the hepatitis C virus (HCV). While 
they are quick to point out that the 
drug, N-nonyl-DNJ, stopped only a 
surrogate virus—and not the actual 
HCV—from reproducing in the lab, 
they believe the findings, which build 
on their earlier success against 
hepatitis B virus (HBV), may someday 
lead to a single drug against both 
viruses. 
HCV chronically infects some 100 
million people worldwide, with as 
many as four million chronic carriers 
in the United States. Those at risk for 
contracting HCV include intravenous 
drug abusers, and anyone who had 
transfusions prior to 1990, when blood 
supply screening for HCV began. 
Together, HBV and HCV chronically 
infect more than 400 million people. 
Approximately one million die each 
year from related liver diseases, such 
as hepatitis, cirrhosis, and cancer. 
Timothy Block, Ph.D., Professor of 
Biochemistry and Molecular 
Pharmacology at Jefferson, and 
colleagues at Oxford University in 
England used N-nonyl-DNJ to inhibit 
the activity of glucosidase, an 
important cellular enzyme. This in 
turn prevented the bovine diarrhea 
virus, BVDV, which is a tissue culture 
model of HCV, from making more 
virus. Because HCV cannot be grown 
in the lab, researchers use BVDV as a 
testing model. 
Dr. Block believes glucosidase 
inhibitors have a reasonable 
likelihood of working against HCV. 
"N-nonyl-DNJ is the first drug since 
alpha-interferon to my knowledge for 
which there is published experimental 
evidence against HCV—in the form of 
BVDV susceptibility," says Dr. Block. 
The drug may sidestep resistant 
viruses, the bane of current anti-
hepatitis treatments. "Since the drugs 
target a host cellular enzyme at very 
nontoxic doses, rather than the virus, 
we think that resistance to the drugs 
will not be a problem," he says. The 
findings appeared October 12 in 
Proceedings of the National Academy 
of Sciences. 
Viruses such as HCV, HBV, and 
BVDV reproduce by budding out 
from intracellular membranes. The 
viruses appear "extremely sensitive to 
these drugs, while the normal cellular 
processes are not affected," Dr. Block 
says. "And because we target this cell 
pathway, upon which a whole family 
of viruses is dependent, we can 
probably develop drugs that have 
broad activity" against an array of 
viruses. 
The next steps are to experimentally 
test the drug against HCV and to 
determine why the virus is so 
sensitive. Potential clinical trials for 
the drug are still some time away. 
In earlier work, and Dr. Block and his 
colleagues at several institutions 
found that N-nonyl-DNJ interfered 
with a specific step in the life cycle of 
the woodchuck hepatitis virus (an 
animal model for HBV), essentially 
shutting down its ability to infect a 
cell. As a result, levels of the virus in 
the animals' bloodstream dropped 
dramatically. 
They found that a very specific step in 
the life cycle of the virus can be 
selectively inhibited by N-nonyl-DNJ. 
The drug worked by inhibiting the 
first step in the glycosylation process 
that all cell glycoproteins go through 
to reproduce. The virus cannot infect 
if it doesn't go through this step. 
Fortunately, the host cellular 
glycoproteins appear to be far less 
sensitive to this inhibition than is 
HBV, meaning that the animal's own 
cells are not badly hurt by the drug. 
BVDV and HCV are viruses composed 
of RNA, as opposed to HBV, which is 
made up of DNA. "They have 
different genomes but similar 
methods of envelope development: 
budding from the endoplasmic 
reticulum (ER)," Dr. Block says. "We 
think they will all be very sensitive to 
N-nonyl-DNJ, since this drug blocks 
the first step in ER glycoprocessing 
which is needed for some but not all 
proteins to fold in the ER." In both 
HBV and HCV, the researchers were 
able to block the creation of a virus 
envelope, locking the virus within the 
infected cell. The virus thus was 
rendered noninfectious. it 
First Transgenic Mouse Model of Hepatitis B-based Disease 
Jefferson faculty have developed the ) first mouse model of chronic liver 
disease caused by hepatitis B virus 
(HBV), which promises to accelerate 
the discovery of drugs against the 
disease. 
Mark A. Feitelson, Ph.D., Professor of 
Pathology, Anatomy, and Cell 
Biology, and his colleagues have 
developed transgenic mice that are 
chronic carriers of HBV. They were 
made by introducing the HBV genetic 
information into mouse eggs, and 
breeding mice that had viral DNA in 
all of their cells. Such mice consis-
tently replicate HBV throughout their 
lives. Although other similar models 
have been made using normal mice, 
none develops chronic liver disease 
because the immune system sees the 
virus as "self' during embryonic 
development. 
To solve this problem, Dr. Feitelson 
used severe combined immunodefi-
cient mice as viral hosts. These mice 
lack critical immune system elements 
that normally would fight the virus. 
When the mice are reconstituted with 
a normal immune system in a 
procedure akin to bone marrow 
transplantation, they do not recognize 
the virus as "self' and develop liver 
disease. 
The researchers reported their results 
in August in the journal Nature 
Medicine. 
"The mice see the virus as foreign, 
which is what they should do," 
Feitelson explains. This is similar to 
the way the human immune system 
recognizes HBV shortly after exposure 
to the virus. 
In addition to chronic liver disease, 
these mice have also been manipu-
lated to develop acute disease. "The 
differences between acute and 
chronic disease in these mice will be 
key to the development of new 
approaches against the latter," 
Feitelson says, noting that many 
individuals with acute disease 
recover. 
continued on page 23 
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INVESTIGATIONS 
GM1 Ganglioside to Improve Parkinson's Symptoms and Delay Its Advance 
Scientists at Jefferson, armed with a new $2.4 million grant from the 
National Institutes of Health, hope to 
find out whether the drug GM1 
ganglioside can improve symptoms, 
delay disease progression, and in 
some cases actually restore damaged 
brain cells in Parkinson's disease 
patients. More than one million 
people in the United States suffer 
from Parkinson's. 
Jay S. Schneider, Ph.D., Professor of 
Pathology, Cell Biology, and 
Anatomy, is leading a five year 
clinical trial involving 150 patients. It 
will compare the effectiveness of GM1 
ganglioside—a naturally occurring 
substance in the nerve cell's 
membrane that plays a role in cell 
growth, development, and repair—to 
standard Parkinson's disease 
treatments, which improve symptoms 
but do not alter the disease process. 
"We hope that we will be able to do 
something no one else has done 
before: to stimulate remaining brain 
cells to sprout new nerve endings and 
rescue other cells that might 
otherwise die," says Dr. Schneider, 
who last year published evidence in 
the journal Neurology showing that 
GM1 may improve symptoms and 
perhaps even help slow progression 
of Parkinson's. 
"If we can stimulate repair and 
regrowth in humans as we've done in 
the laboratory, we will have evidence 
for the first time of a therapy that can 
help restore the part of the nervous 
system damaged by a neurodegener-
ative disease," Dr. Schneider says. 
"Current therapies for Parkinson's 
disease treat only the symptoms and 
do little to address the underlying 
disease. You can alleviate some 
symptoms for a time, but the 
neurodegeneration continues." 
The Jefferson team is collaborating 
with scientists at the University of 
Pennsylvania to perform a special 
type of imaging called single photon 
emission computed tomography, or 
SPECT. It allows the team to visualize 
the number of dopamine terminals in 
the striatum, the part of the brain that 
receives dopamine from the 
substantia nigra (the brain region that 
dies in Parkinson's disease). 
Comparing patient symptoms and the 
number of dopamine terminals is a 
significant advance, Schneider notes. 
"This technology will give us insight 
into the relationship between the 
expression of Parkinsonian 
symptoms, and the actual number of 
dopamine terminals in the brain." 
The study is a randomized, double 
blind, placebo controlled trial in 
which neither the researchers nor the 
patients know who receives the drug. 
Patients with mild to moderate 
Parkinson's disease will be divided 
into three groups of 50 each. One 
group will receive the drug during the 
first two study phases. Another 50 
will receive a placebo during phase 
one, and the drug during the second 
trial phase. A third control group of 
50 will receive neither the study 
medication nor a placebo, but will 
receive standard Parkinson's therapy. 
This latter group will have the option 
of receiving the new experimental 
medication after the study period 
ends. 
"We're hoping that in the first six 
months of the study we'll see the 
same kind of symptomatic 
improvement we've seen in previous 
studies with GM1, as well as a small 
increase in the number of dopamine 
terminals," Schneider says. 
Can Melatonin Help Avoid Parkinson's Damage? 
Melatonin, a substance now familiar to consumers, could 
be a key to understanding how to 
treat Parkinson's disease. Scientists at 
Jefferson have shown in the 
laboratory and in test animals that 
melatonin is effective in preventing a 
type of brain cell damage similar to 
that found in Parkinson's. 
It's widely believed that the loss of 
dopamine nerve cells seen in 
Parkinson's patients' brains, results 
from oxidative stress to the cells. 
Various cellular insults produce 
oxygen free-radicals, resulting in cell 
death. The brain's dopamine neurons 
are particularly vulnerable. 
Melatonin, a hormone produced by 
the brain which is marketed commer-
cially as an anti-aging agent, is the 
body's most potent antioxidant. Two 
years ago, Professor of Neurology 
Lorraine lacovitti, Ph.D. and her 
coworkers showed in the laboratory 
that melatonin was effective in 
blocking the oxidative ravages of 
Parkinson's-damaged dopamine-
producing cells. They tested the 
theory in rats by giving the animals a 
toxin, 6-hydroxydopamine, which 
specifically damages dopamine 
neurons, producing a Parkinsonian-
like syndrome. They found that by 
injecting melatonin into the rats 
either 10 minutes prior to the 6- 
hydroxy infusion, or 30 minutes 
afterward, they could block the 
Parkinsonian effects. If they adminis-
tered melatonin 120 minutes later, 
they were able to prevent about half 
the damage, or "rescue the cells." 
Dr. Iacovitti presented her team's 
findings October 24 at the annual 
meeting of the Society for 
Neuroscience. 
In oxidative stress, cells don't automat-
ically die. Rather, they pass through a 
cascade of cellular events leading to 
cell death. lacovitti and her team used 
melatonin to stop the cascade at its 
beginning. They plan to explore other 
checkpoints in the death cascade to 
gauge the compound's effectiveness. 
"If you get enough antioxidants to the 
dopamine nerve cells, you might be 
able to prevent the kinds of oxidative 
stress and cell death you see in 
Parkinson's," she believes. Dr. 
lacovitti notes that melatonin "has 
the correct action to be developed 
pharmaceutically," but cautions that 
the dosages given to the test animals 
were extremely high. "Whether it 
could be developed into a safe drug is 
another question," she says. "It's 
difficult to know at what levels to 
keep antioxidants in the body." A 
drug company might be able to 
isolate an active part of melatonin 
that could be a more effective antiox-
idant at lower doses. it 
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Stimulating Learning Environment 	 Jefferson Ranks in the Top Quarter of 
May Prevent Alzheimer's 
A study by a Jefferson scientist 	 balls, a maze, and a bar-pressing food 
n.suggests that a stimulating learning 	 station. They could choose their food 
environment early in life might help 	 and treats, such as corn chips. Rats 
ward off neurodegenerative diseases 	 living in standard conditions had no 
later. Nurture may be more influential 	 toys and only one food and water 
than nature when it comes to the brain's source. 
resilience to injury. 
Other scientists have shown in recent 
Researchers at Jefferson and the 	 years that brain cell growth and 
University of Auckland in New Zealand 
	 replacement can occur throughout 
found that rats living in a stimulating 	 development and aging in animals 
environment filled with running wheels, and humans, while brain cell death 
tunnels, balls, and food had 45 percent 	 also occurs. The work by During's 
less of the brain cell death commonly 	 team provides the first compelling 
associated with normal development and evidence that a stimulating 
aging, than did rats living in basic 	 environment along with early and 
surroundings. What's more, when the 	 continued learning not only protects 
stimulated rats were exposed to a 	 the brain from disease, but increases 
neurotoxin, they suffered almost no loss its capacity to repair and regrow 
of brain cells, unlike those in a normal 	 damaged cells. "We've shown that a 
environment. The results were reported 	 learning environment can encourage 
in the April 1999 issue of Nature 	 cell growth, and also reduce cell 
Medicine. 	 death by about 45 percent (including 
both aged cells and young 
"We were hoping to find 
some scientific underpin-
nings to the age-old maxim 
'use it or lose it,' " explains 
Matthew During, M.D., 
Director the Central Nervous 
System Gene Therapy Center 
at Jefferson. 	
During 
Dr. During was surprised how robust the 
brains were in rats in a stimulating 
environment. "We showed in this study 
that an enriched environment switched 
	
During and his coworkers are now 
on genes in the brain. By this 	 unraveling the mechanism: the 
mechanism, the brain appears to become specific environmental components 
resistant to aging, or traumatic brain 	 and specific interventions that are 
injury, or diseases such as Alzheimer's 	 effective in protecting the brain. 
and Parkinson's," he says. 	 "We're asking whether these genes 
we've shown to be active are actually 
"There haven't been many proper studies switched on by the environment. 
done in the lab to show whether actively What specific genes and chemicals are 
using your brain enhances your ability to involved? And can we use them to 
stay healthy, and what specific 	 improve protection of the brain, and 
mechanisms might be involved in this. 	 to treat neurodegenerative diseases?" 
We asked what a stimulating 	 Among the chemicals associated with 
environment would do to cognitive 	 these processes are growth factors, 
function, particularly in preventing brain such as glial cell derived neurotrophic 
cell death and brain degeneration." 
	
factor and brain derived neurotrophic 
factor, and transcription factors. 
The enriched learning environment for 
rats had running wheels, tunnels, rubber 
111 0 
All Medical Schools in Training Grants 
efferson Medical College now ranks among the top 25 percent of all 
medical schools in the United States in terms of training grants from the 
National Institutes of Health. 
Of 124 medical colleges receiving NIH training grants, Jefferson is now 30th, 
notes Gerald Litwack, Ph.D., Associate Dean for Scientific Affairs. The 
ranking is based on an analysis conducted by Dr. Samuel Herman, Jefferson's 
liaison to the NIH in Bethesda, Maryland. "Many scientists believe that a 
training grant is an indicator of the significance of the research being 
conducted," Litwack points out. 
In terms of total NIH research dollars, Jefferson is 40th nationally, or within 
the top third of all medical schools, Dr. Litwack adds. Amount of NIH 
funding is widely seen as an indicator of an institution's quality. "Jefferson is 
currently embarked on an organized effort to move up to the top 25 percent 
in total NIH dollars," he says. 
"For the fiscal year ending June 1999, our research income, including NIH 
and all other sources, is estimated at more than $94 million. This is roughly 
a $10 million increase over the previous year." 
Jefferson currently has about 17 NIH-supported training grants, totaling 
more than $2.5 million per year for training. Helping boost Jefferson into the 
top 25 percent in this area is a recent $1.2 million award to Jefferson's 
Department of Biochemistry and Molecular Pharmacology from the National 
Institute of Diabetes, Digestive and Kidney Diseases. The five year grant pays 
stipends for four postdoctoral and four predoctoral fellowships in 
biomolecular signal transduction. The NIH-funded faculty preceptors come 
equally from the Department of Biochemistry and Molecular Pharmacology 
and from Jefferson's Kimmel Cancer Institute. 
Three of the current NIH training grants are for medical students, for 
summer research in cancer and blood and lung disease as well as other areas, 
Dr. Litwack adds. "Our success in funding medical students' summer 
research outpaces many notable medical schools. Every summer we generate 
35 slots for first year medical students who wish to experience research." 
These positions are funneled through the Office of Scientific Affairs and 
coordinated by Professor Catherine Calkins, Ph.D. 
To further increase our funding from the NIH, in order to reach our goal of 
the top 25 percent, Litwack says, "Our plans are to increase the size of our 
faculty and our research facilities." 
It is likely that in the year 2002, many of the researchers and clinicians of the 
Kimmel Cancer Center will move into a large new building of their own on 
Jefferson's campus. The new structure will mean a major expansion of the 
total lab space on campus, enabling Jefferson to recruit many more investi-
gators and obtain significantly more federal grant money, including training 
grants, than at present. 
A further step in the 
Jefferson study was to give 
both sets of rats kainic 
acid, a neurotoxin. The 
brains of rats in the 
enriched surroundings 
were almost completely protected—a 
dramatic finding. 
cells that spontaneously 
die)." 
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JEFFERSON HEALTH SYSTEM 
Senior Health Institute Will Guide Care to the Aging 
Medical progress during the 20th century has dramatically 
increased life expectancy. An ever 
larger percentage of the population is 
over age 65. Many of these 
individuals have chronic age-related 
conditions such as osteoarthritis, 
heart disease, or dementia. Others 
have so far remained healthy. 
Recognizing their varying needs, the 
Jefferson Health System has 
developed a Senior Health Institute to 
guide its efforts to improve the 
quality of life of older persons. The 
SHI draws on the expertise of 
numerous system members in 
research, teaching, and clinical 
practice. The objectives are: 
1. To foster the development, 
quality, and integration of services 
for seniors. 
The institute has created an inventory 
of existing JHS senior health 
resources, with a database accessible 
via the World Wide Web to increase 
awareness of them. Elizabeth White, 
M.D., a board certified geriatrician, 
has been appointed Medical Director 
of Senior Health for the system. She is 
organizing the medical directors of 
long term care facilities throughout 
JHS to develop quality criteria for 
physicians, and quality measurement 
processes for resident care. Dr. White 
is also designing wellness programs 
to prevent illness and disability in 
assisted-living and continuous care 
retirement communities. 
2. To promote aging research 
within JHS. 
Laura Gitlin, Ph.D., Director of 
Community and Homecare Research 
at Thomas Jefferson University's 
College of Health Professions, has 
compiled an inventory of researchers 
in basic science, clinical medicine, 
and gerontology to stimulate interdis-
ciplinary and inter-institutional 
research. The computerized inventory 
will be accessible via the SHI Web 
page, to make it easy to search for 
investigators across the system. 
Dr. Gitlin is also preparing a 
leadership grant application to the 
National Institute on Aging. The 
research goal is to develop methods 
to identify persons at high risk for 
disability, and provide them with 
services to optimize their health and 
prevent health-related crises. This 
involves appropriate screening, 
utilization of treatment protocols 
and clinical guidelines, and coordi-
nation of medical and support 
services efficiently across multiple 
health care sites. 
3. To create "senior friendly" 
medical settings. 
"Senior sensitive" hospitals and 
clinics will have innovative environ-
mental and procedural refinements 
to improve hospital experiences for 
older patients. The changes will 
include early rehabilitation, 
minimization of adverse effects of 
medications, and formulation of 
thoughtful discharge plans. 
4. To enhance education 
in geriatrics. 
The directors of training programs 
throughout Thomas Jefferson 
University and the health system are 
developing curricula for medical 
students, nurses, occupational 
therapists, and physical therapists to 
cover such areas as functional 
assessment, theories of aging, 
expected physiologic changes, the 
continuum of long term services, and 
the special needs of caregivers. 
Market forces have substantially and 
perhaps adversely affected medical 
practice in this country. For older 
adults, misaligned incentives and 
fragmented services have perpetuated, 
if not exaggerated, the preexisting 
deficiencies. We want to tap the 
ingenuity and commitment across the 
Jefferson Health System to protect 
and restore the health of older 
persons. 
—Barry W. Rovner '80, Medical 
Director of the Wills Geriatric 
Psychiatry Program, a joint 
program of Jefferson and the 
Wills Eye Hospital 
Lankenau Receives One of Five Grants Nationwide 
to Study the Basic Biology of Aging 
researchers led by Dr. Vincent J. Cristofalo at he Lankenau Medical Research Center, a 
member of the Jefferson Health System, are the 
recipients of a large grant from the National 
Institute on Aging for a Nathan Shock Center of 
Excellence in the Basic Biology of Aging. This is 
one of only five grants in the United States, the 
others being at Harvard University, the University 
of Michigan, the University of Texas at San 
Antonio, and the University of Washington. 
The award carries funding over a four-year period 
to enhance support facilities for investigations and 
provide a stimulating environment to new 
researchers in the field. 
Three overlapping and interrelated themes 
underlie the program of the Nathan Shock Center: 
functional changes in excitable tissues such as 
nerve, muscle, and heart, including dementing 
diseases such as Alzheimer's disease; changes in 
the regulation of gene expression with aging, 
including those changes leading to age-associated 
diseases such as cancer, atherosclerosis, or 
osteoarthritis; and mechanisms of regulation of the 
declining function of the immune system. 
The grant currently supports five core resource 
units around which the research is structured. The 
Animal Core offers properly housed and geneti-
cally defined rodents of different ages to qualified 
researchers. By providing genetically defined 
female rats to expand studies done previously on 
males, this core promotes research on sex differ-
ences in life span and patterns of aging. The Cell 
and Tissue Core involves expanding an existing 
human cell bank and establishing a human tissue 
bank. The Brain Bank Core makes available brain 
tissue from human subjects with an emphasis on 
nonpathologic brain specimens. 
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Kimmel and Whitney Elected to Board of Trustees Jefferson 
HealthCARE 
Opens in Voorhees 
A s part of its continuing effort to 
.1.provide health care services to 
the South Jersey population, 
Jefferson HealthCARE-Voorhees has 
opened in the Voorhees Corporate 
Center. The new facility houses 
medical offices and general x-ray 
services. A wide array of specialties 
are represented, in addition to 
primary care. 
"Now we can care for patients who 
are seeing Thomas Jefferson 
University Hospital physicians, but 
don't want to travel too far from 
home," explains Jefferson Hospital 
President and CEO Thomas J. Lewis. 
"Many of our doctors who practice in 
Center City already treat patients 
who live in South Jersey. By bringing 
the doctors closer to where they live, 
and providing a variety of specialists 
under one roof, we have shortened 
the distance between Jefferson and 
our patients." 
Jefferson Hospital was named this 
year by U.S. News and World Report 
as one of "America's Best Hospitals" 
for cancer treatment, cardiology, 
gastroenterology, geriatrics, 
gynecology, neurology and 
neurosurgery, orthopaedics, 
otolaryngology-head and neck 
surgery, respiratory disorders, 
rheumatology, and urology. it 
rpie Board of Trustees of Thomas 
Jefferson University has elected 
two new members: Sidney Kimmel 
and Leslie W. Whitney, M.D. 
Mr. Kimmel is founder and chairman 
of the Jones Apparel Group, a leading 
women's apparel manufacturer. He 
has long been active in supporting 
medical, cultural, and educational 
organizations nationally, with a 
particular focus on the Delaware 
Valley. 
Mr. Kimmel is perhaps best known to 
Jeffersonians through his generous 
gifts to establish the Kimmel Cancer 
Center of Jefferson Medical College 
and the Kimmel Cancer Institute for 
research. As National Chairman of 
Transgenic Mouse Model, from page 19 
The mouse model may also have 
implications for developing drugs to 
fight a major international public 
health dilemma. "One of the largest 
problems in the field of hepatitis B is 
what to do with carriers at high risk 
for the development of chronic liver 
diseases," Feitelson notes. "We have a 
vaccine to prevent the disease and 
tests to screen the blood supply, but 
there are still an estimated 350 
million HBV carriers at high risk of 
developing hepatitis, cirrhosis, and 
liver cancer." As many as two billion 
people worldwide are infected with 
the virus, though they are not 
carriers. Chronic HBV infection is the 
"The March," Mr. Kimmel 
spearheaded a program last year in 
Washington, D.C., that resulted in an 
unprecedented 16 percent increase of 
$400 million in federal funding for 
cancer research. 
Mr. Kimmel has produced major films 
through his entertainment company 
and has been the lead supporter of his 
native Philadelphia's performing arts 
center, currently under construction 
as the new home of the Philadelphia 
Orchestra. 
Leslie W. Whitney, M.D. has pursued 
a long and noteworthy career in 
medicine in Delaware and 
Philadelphia, with an emphasis on 
cancer treatment, education, and 
research. 
ninth leading cause of death in the 
world, accounting for a million 
deaths annually. 
While scientists know that the 
pathogenesis of chronic hepatitis B is 
due to immune responses against the 
virus-infected liver cells, "There are 
basic science questions about the 
pathogenesis that are unsolved and 
which can be addressed using our 
new mouse model," Feitelson says. 
"We can test drugs in the liver against 
the virus in the absence of disease—if 
we don't reconstitute the immune 
system. Or we can replace the 
immune system and then ask what 
the drug does to the virus and the 
disease." 
Since 1994 he has served as Director 
of Academic Affairs at the Medical 
Center of Delaware, and since 1996 as 
Assistant Dean at Jefferson Medical 
College. Since 1995 he has been 
Executive Director, Delaware 
Institute for Medical Education 
(DIMER) and since 1994 has chaired 
faculty committees on quality 
improvement, clinical care, and 
credentialing for the Medical Center 
of Delaware in addition to serving as 
Medical Director, Health Services 
Corporation, Medical Center of 
Delaware. Dr. Whitney is a Trustee of 
the Medical Center of Delaware 
Foundation. He has been principal 
investigator for numerous cancer 
research projects in Delaware through 
the years. it 
The mouse model will enable 
scientists to target the liver with viral 
gene therapy, decide which virus 
proteins are targets for immuno-
logical responses, and identify the 
parts of the immune system that are 
important for targeting the virus. 
The model has implications for 
understanding other diseases as well. 
"Scientists can use the same approach 
to study the pathogenesis of immune-
mediated diseases involving other 
infectious agents—and to study 
certain autoimmune diseases," he 
explains. "With something that is 
foreign, you can reconstitute the 
immune system and look for 
development of pathology to that 
foreign protein." it 
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SS veraTZENTI-e 
ECKTROgy. 
B 0 0 K S 	 The "Best" Internet Sites about Health 
Arthur H. Brownstein '80 is the 
author of Healing Back Pain Naturally, 
published this year by Harbor Press 
of Gig Harbor, Washington. The book 
has been endorsed by Andrew Weil, 
M.D., a well known advocate of 
alternative therapies. Dr. Brownstein 
holds an M.P.H. in addition to his M.D. 
degree, and is a Clinical Instructor of 
Medicine at the University of Hawaii. 
He lives in Hanalei. 
Richard Spaide '81, author of 
numerous papers, book chapters, and 
invited lectures, had a textbook, 
Diseases of the Vitreous and Retina, 
published by W. B. Saunders Company 
in August. Dr. Spaide has a large 
practice in New York City, and a 
faculty affiliation with New York 
Medical College. His wife Chang Ho 
Spaide is an '83 Ph.D. graduate of 
Jefferson. 
AIDE 
DISEASES 
THE RETINA 
AND VITREOUS 
Mark R. Stein '68 of Palm Beach 
Gardens, Florida is the Editor of 
Gastroesophageal Reflux Disease and 
Airway Disease, published this year by 
Marcel Dekker, New York as part of 
the series "Lung Biology in Health 
and Disease." Dr. Stein's volume 
comprises 364 pages with illustra-
tions. Among the 13 contributors are 
Lyndon Mansfield '68 of El Paso, 
Texas and Stephen McGeady, M.D., 
a faculty member in pediatric allergy 
and clinical immunology at Jefferson 
and the duPont Hospital for Children. 
Five Jefferson alumni contributed to 
the new centennial edition of The 
Merck Manual. Seventeen editions of 
this well known book have been 
published since 1899 as a nonprofit 
informational source by Merck and 
Company, the pharmaceuticals firm. 
More than 10 million copies in 16 
languages have been sold in this 
century. Rest assured, the content has 
changed: where the 1899 manual 
recommended leeches for laryngitis, 
this year's volume discusses resistance 
to antibiotics. Instead of tobacco as a 
treatment for asthma, there's now a 
chapter on smoking cessation. 
The 1999 section on myoneurogenic 
disorders and prostate disease was 
contributed in part by Gerald Andriole 
'78, Chief of Urology at Washington 
University School of Medicine in St. 
Louis. Stephen Finn '92 of Georgia 
wrote on gastritis and peptic ulcer 
disease. John H. Bland 144, a Professor 
Emeritus at the University of Vermont 
College of Medicine, covered 
osteoarthritis and neurogenic 
arthropathy, and Herbert Patrick '77, 
a Jefferson faculty member and expert 
on pulmonary medicine, discussed 
sarcoidosis. James V. Macke!! '69 of 
Maple Glen, Pennsylvania'was a 
chapter reviewer. 
Wen Jefferson neuroscientist Jay . Schneider, Ph.D., tried to 
navigate the Internet in search of 
information to help a neighbor learn 
more about his daughter's rare brain 
tumor, he was perplexed by the 
difficulty of wading through vast 
reams of material, some of it blatantly 
inaccurate. 
How, he asked, could the average 
person possibly separate the helpful, 
accurate information from the useless 
and misleading? 
"A typical search may result in a list of 
thousands of sites containing your 
search word or phrase," says Dr. 
Schneider, a renowned Parkinson's 
disease expert and Professor of 
Neurology at Jefferson. "Out of those 
sites, some have erroneous medical 
information, and some are simply 
trying to sell products." 
Finding no consumer guide to help, he 
and a colleague decided to write one. 
Dr. Schneider and fellow neurosci-
entist Theodore I. Lidsky, Ph.D., 
Director of the Laboratory of 
Electrophysiology at the Institute for 
Basic Research on Developmental 
Disorders in Staten Island, New York, 
created a guide entitled The Doctor's 
Always In. Published by 
Neurolnformatics Publishing, it 
describes more than 1,100 "best" 
Internet sites on health and medical 
information. 
The book's 25 chapters are broken 
down by body system and specific 
disease category, such as AIDS, 
allergies/asthma, cancer, gastroen-
terology, mental health, or sports 
medicine. Nearly every chapter begins 
with a "general information resources" 
section describing information on a 
range of topics. This is followed by 
descriptions of more specific sites. 
Each entry gives the web address and 
explains what the consumer can 
expect to find. 
In the chapter on cancer, for example, 
the first few pages describes more 
general cancer information sites. The 
rest of the chapter focuses on specific 
sites, such as those for brain tumors, 
childhood leukemia, and breast 
cancer. A chapter on alternative 
medicine offers descriptions of sites 
focusing on herbal medicine, 
medicinal plants and foods, 
chiropractic, and homeopathic 
medicine. 
The authors also include a chapter 
entitled "General Medical Resources," 
which describes sites providing 
material about drugs, clinical trials, 
and consumer information about 
doctors. 
"In researching the book, we combed 
through thousands of sites for more 
than six months to find those that 
had reliable information. Many of 
these were from government organi-
zations, foundations, and academic 
institutions," Dr. Schneider explains. 
Some institutions such as Jefferson 
(www.jeffersonhealth.org) provide 
both timely news and comprehensive 
information on a wide range of 
medical subjects. 
"We also provide some cautionary 
notes about getting medical 
information from the Internet, which 
can be very different than getting it 
from a book or a physician. 
"The book makes you a more 
educated consumer, allowing you to 
discuss your condition, medications, 
or side effects with your doctor," Dr. 
Schneider says. 
The authors also include an 
explanation of how the Internet 
works, including such features as 
bulletin boards, listservs, and search 
engines. 
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History of the Art Collection 
at Thomas Jefferson University 
Julie S. Berkowitz 
Jefferson Art Book Now Available 
A unique addition to the annals of Jefferson history, "ADORN THE HALLS": History of the Art Collection at Thomas Jefferson University, 
has been written by Julie S. Berkowitz, the University Art Historian. The 725 page book was edited by Malcolm Clendenin, Editor of the Jefferson 
Alumni Bulletin. 
The richly illustrated medical/art book describes the origins and development of the Jefferson collection, comprising paintings, sculptures, 
architecture, decorative arts, photographs, prints, drawings, and rare medical books. Following a survey of the collection as a whole, 10 chapters 
trace Jefferson's chronological history in the context of its portraits and other art works which collectively delineate the spirit of the institution. 
The final two chapters treat nonmedical art objects (such as landscapes) and European medicine and its practitioners. 
The handsome volume contains black and white photographs of 429 art works (several with closeup details), and full color photographs of 28 
objects. The hard cloth cover is stamped in gold, and the dust jacket features Thomas Eakins's The Gross Clinic. This monumental painting is 
discussed in its own chapter, preceded by a chapter treating Eakins as a scientist and his relationship with Jefferson Medical College. 
Send Mail Order Form to:  Thomas Jefferson University Bookstore, 224 S. 1 1 th St., Phila., PA 19107; 
for further information call (888) TJU-BOOK or fax (215) 923-1844 
Quantity 	 Amount 
Each book 
	 $79.00 
UPS Shipping per book 	 6.00 
Each additional destination 	 6.00 
TOTAL 
Check or Money Order Enclosed, Drawn on a U.S. Bank in U.S. Currency 
Please Make Check Payable to: Thomas Jefferson University Bookstore 
For Visa/MasterCard/AmericanExpress/Discover 
Account No. 	  
Expiration Date 	  
Signature 	  
Name 
	  
Address (no P.O. box, please) 
	  
Telephone No. ( 	  
The Holidays Are Here—Please Send a Book as a Gift to: 
Name 
	  
Address (no P.O. box, please) 
	  
Please enclose your own gift card with message, and the bookstore will send it with your gift. 
Lankford Receives Biomedical 
Engineering Grant from the 
Whitaker Foundation 
Edward Lankford, M.D., Ph.D., Assistant Professor of Pathology, 
was one of 20 researchers from 19 
universities who recently received 
Biomedical Engineering Research 
Grants from the Whitaker 
Foundation. 
These grants help promising new 
investigators establish research 
careers. Dr. Lankford's award of 
$210,000 will support his research 
on the functional recovery of failing 
cardiomyocytes. He will explore 
changes that occur in human hearts 
after they undergo placement of 
implanted pumps. Such devices, 
which assist the failing heart by 
pumping blood, are inserted in 
individuals awaiting heart 
transplants, who otherwise might not 
survive until a heart is available. 
It has been observed that patients' 
hearts, when supported by these 
devices, shrink and begin pumping 
more strongly, and Dr. Lankford 
hopes to understand the cellular 
changes that are responsible for this 
improvement. This, in turn, may 
enable physicians to understand why 
the heart function deteriorates and 
lead to a dramatically better 
alternative to heart transplantation 
for treating heart failure. The 
research requires the design, 
construction, and use of a new device 
to study very small samples of 
human heart tissue, especially the 
tissue's ability to contract and 
perform work. 
"Since heart failure is the most 
common reason for hospitalization 
today and there is an insufficient 
number of hearts available for 
transplantation, most patients will 
not receive transplants," Dr. 
Lankford noted. "Therefore, we need 
to be able to coax the failing heart 
into sustaining the patient's life and 
some level of activity for as long as 
possible. This research should help 
us understand how the heart muscle 
cells adapt to the load imposed on 
them, and allow us to design dramat-
ically new therapy for heart failure. 
We are very excited about the 
potential of this research that we will 
be able to conduct with the three-
year Whitaker Foundation grant." 
The Whitaker Foundation of 
Rosslyn, Virginia is a private, 
nonprofit foundation dedicated to 
improving human health through the 
support of biomedical engineering. It 
was established in 1975 upon the 
death of U. A. Whitaker, founder and 
Chief Executive Officer of AMP 
Incorporated, now the world's largest 
manufacturer of electrical connectors 
and connecting devices. The 
foundation has awarded more than 
$450 million to colleges and univer-
sities for faculty research, graduate 
fellowships, and program 
development in biomedical 
engineering. 
Another recipient of a Whitaker 
Foundation grant is Jefferson 
alumnus Mark Brezinski 
M.D./Ph.D.'88, who currently teaches 
at Harvard Medical School and 
Massachusetts General Hospital. 
FACULTY KUDOS 
Michael A. Alexander, M.D., Clinical Professor of 
Rehabilitation Medicine at Jefferson and an expert on 
pediatric rehabilitation, takes office at the end of 1999 
as President of the Medical Society of Delaware. 
Paola Luzi, Ph.D., Research Instructor in Neurology, 
has received an award of $30,000 from the Hunter's 
Hope Foundation of Orchard Park, New York. The 	 Alexander 
grant supports Dr. Luzi's pilot research into gene 
therapy that may provide a novel delivery system for treatment of Krabbe 
disease. 
Krabbe disease (globoid cell leukodystrophy) is a genetic disorder resulting 
from the deficiency of the lysosomal enzyme galactocerebrosidase. It is charac-
terized by the progressive loss of central and peripheral myelin (a protective 
covering that insulates nerve cells), leading to early death. The most common 
form of this disease affects babies, who usually die by two years of age. Krabbe 
disease also affects older children and adults. 
Presently, there is no cure for this condition, and treatment has been 
limited to cold blood and bone marrow transplantation in presymptomatic and 
later-onset patients. The gift from Hunter's Hope will enable Dr. Luzi and her 
colleagues to investigate possible gene therapy. 
Hunter's Hope, founded in 1997, has raised more than $2 million to benefit 
research on Krabbe disease, and has also increased public awareness of this 
disease and other leukodystrophies (which cause degeneration of the white 
matter of the brain). 
Michael Rhodes, M.D., Professor of Surgery at Jefferson and Chair of Surgery 
at Christiana Care Health System in Wilmington, Delaware, received the 
Curtis P. Artz Award from the American Trauma Society during the annual 
meeting in Washington, DC in April. The award is presented to individuals for 
outstanding long term contributions in the field of trauma. 
Henry Rosenberg, M.D., Professor and residency director in Jefferson's 
Department of Anesthesiology, has been named President of the Malignant 
Hyperthermia Association of the United States. MHAUS provides information 
to professionals caring for patients with malignant hyperthermia or 
neuroleptic malignant syndrome. Malignant hyperthermia is a rare inherited 
condition characterized by a rapid, extreme, and often fatal rise in body 
temperature following the administration of general anesthesia. Neuroleptic 
malignant syndrome is a dangerous side effect occasionally seen in patients 
taking neuroleptic drugs for psychotic symptoms such as paranoid delusions 
and auditory hallucinations. 
Dr. Rosenberg is Editor-in-chief of the American Journal of Anesthesiology 
and is an article reviewer for several journals. He has published extensively on 
malignant hyperthermia. 
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Jefferson students are a very select group: the 
223 members of the Class 
of '03 were chosen from a 
total of 8,171 who applied 
for admission. Members of 
this class hail from 22 
different states as well as 
Canada, and attended 91 
different colleges. Forty-six 
percent of the class is 
female. No fewer than 34 
students already hold 
master's degrees; two have 
Ph.D.s. Ages range from a 
very young 19 up to a wise 
44. The age range reflects 
the fact that many have 
already achieved 
distinction in other careers. 
Krissa George balances the books with 
motherhood: on the first day of the semester, 
bookbag over her shoulder, she tends to young 
Annalise. Before coming to Jefferson, Krissa was 
a health administrator for an international 
finance firm, as well as a mother of two. 
Health care is familiar to many of them: there are a handful of nurses, a clinical 
epidemiologist, a researcher in an academic program in bone marrow 
transplant, an infants' nutrition counselor, a pharmacist, a pediatric audiol-
ogist, a researcher in a hospital department of maternal-fetal medicine. One 
has been a professional counselor for victims of sexual assault or domestic 
violence. 
One new student spent two years as a Peace Corps volunteer in Guinea, West 
Africa, teaching calculus in French to high school students. Another 
volunteered in Croatia, working with refugee children. A third volunteered in 
Mother Theresa's hospital in Calcutta, India. 
We know that Jefferson students can perform: there are a concert cellist, a 
classical guitarist, a professional clown, and a TV comedy writer. But 
management skills are not lacking: one freshman was a director of interna-
tional sales for a computer game company. And technical skill is taken for 
granted: there are several engineers, including one specializing in submarines. 
The Class of 2003 was selected under the leadership of Benjamin Bacharach 
'56, who served until recently as Associate Dean for Admissions, and is now 
Associate Dean for Alumni Relations and Acting Executive Director of the 
Alumni Office. The selection of next year's entering class is now being 
overseen by Clara A. Callahan PD'82 as Associate Dean for Admissions and 
Student Affairs. it 
At right: Associate Director of Admissions Grace Hershman and Assistant Dean 
for Student Affairs Karen Glaser, Ph.D. with first year student Denise Markmann 
(second from right) and her parents Margaret and William Markmann ORS'79 
STUDENT ADMISSIONS 
The* Class of 2003 JAMA Study Proves That PSAP Brings 
Family Physicians to Underserved Areas 
espite an oversupply of I 
	 physicians in the United States, 
statistics show that rural areas 
continue to suffer from a shortage of 
physicians, especially family doctors. 
In response to this maldistribution, 
Jefferson Medical College initiated the 
Physician Shortage Area Program 
(PSAP) in 1974 to increase the 
number in underserved regions, 
especially in Pennsylvania. 
Now 25 years old, the PSAP, which 
admits approximately 15 students per 
year, graduates 12 percent of all rural 
family doctors in Pennsylvania. A 
retrospective study demonstrating 
PSAP's effectiveness in easing the 
shortage of rural physicians appeared 
in the January 20, 1999 issue of the 
Journal of the American Medical 
Association. 
The program recruits students who 
have grown up in a rural setting and 
who are committed to practicing 
family medicine in a similar area. "The 
selection process of students for the 
PSAP has been key to the successful 
retention rates," explains Howard K. 
Rabinowitz, M.D., Professor of Family 
Medicine at Jefferson and director of 
the PSAP since 1976. 
PSAP students follow a curriculum 
similar to their non-PSAP classmates, 
but receive training in small towns 
and are guided by an academic 
advisor from Jefferson's Family 
Medicine Department. 
The JAMA study used current data on 
206 PSAP graduates from the classes 
of '78 to '91 who are presently 
practicing family medicine in 
underserved areas of Pennsylvania. 
They were compared against all 
allopathic (M.D.) medical school 
graduates in the state, and against all 
U.S. and international graduates. The 
PSAP graduates were also compared 
against their non-PSAP peers from 
Jefferson Medical College regarding 
their U.S. practice location, medical 
specialty, and retention for the past 
decade. 
Results show that PSAP graduates, 
who represent only one percent of the 
graduates of Pennsylvania's seven 
allopathic medical schools, account 
for 21 percent of family physicians 
practicing in rural Pennsylvania 
coming from those medical schools. 
Among all national and international 
medical school graduates, PSAP 
continued 
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Stuffed animals lend support on the right as the boss consults Dr. Turner. 
alumni represent 12 percent of all 
family physicians in rural 
Pennsylvania. Results were similar for 
PSAP graduates practicing in other 
underserved regions. 
Overall, PSAP alumni were eight times 
more likely than their non-PSAP 
classmates at Jefferson to practice 
family medicine in a rural area of the 
U.S. Program retention was also found 
to be high, with the number of PSAP 
graduates practicing in underserved 
areas being approximately 90 percent 
of the number practicing 10 years ago. 
Rural family practice truly means care 
for the family as a whole. Physicians 
treat each generation, providing 
general medical attention plus such 
specialty services as delivering babies 
and minor outpatient surgery. 
"With more rural residents in 
Pennsylvania than in any other state in 
the nation, the medical needs of this 
population are great, and Jefferson's 
PSAP is meeting these needs to a large 
extent," Dr. Rabinowitz says. 
For James Devlin '85, medical training 
began as a child when he accompanied 
his father, a family physician, on 
house calls in Brockway, a small rural 
community in western Pennsylvania. 
A graduate of the Physician Shortage 
Area Program at Jefferson, Devlin 
today practices family medicine in the 
same town, bringing his two children 
with him on house calls, much the 
way his father did a generation ago. 
"Growing up in Brockway, I watched 
my father get to know his patients as 
people, by really sharing in their 
lives," says Dr. Devlin. "I knew that I 
wanted to return to this atmosphere 
and practice medicine in much the 
same way. The PSAP gave me the 
training I needed to care for people." 
Through the PSAP, Dr. Devlin was 
able to take his clinical rotations 
during his junior and senior years of 
medical school in rural parts of 
Pennsylvania. This exposed him to 
A visit to Dr. Devlin is not too scary. 
both inpatient and outpatient 
settings, giving him hands-on 
understanding of how to work in a 
relatively isolated area. 
"It means providing a wide range of 
care for the entire family," Devlin 
explains. In Brockway, he practices 
primary care in the sense most city 
dwellers know it, but also delivers 
babies and assists with various 
surgeries such as gallbladder removal, 
hysterectomy, and caesarean sections. 
Dr. Devlin treats grandparents for the 
general health problems of old age, 
while delivering their great-
grandchildren. "There is a limited 
number of subspecialists here, 
broadening the scope of what I am 
called upon to provide." 
It'll be as good as new in no 
time, Dr. Devlin assures. 
"The PSAP's goal was to return me to 
the place I had loved since childhood. 
I am able to care for patients who are 
also my friends. This is family 
medicine in its purest form. 
Interestingly, it's also very modern: in 
the past decade there's been more and 
more emphasis nationwide on 
primary care." 
A '93 graduate of Jefferson's Physician 
Shortage Area Program, Thane Turner 
of Lock Haven, Pennsylvania has 
experienced the program's benefits 
both as a student and as a teacher. 
Enjoying the history and people of 
Lock Haven, Dr. Turner knew that he 
wanted to return there to practice 
medicine, caring for the friends and 
family he had known for a lifetime. 
"Practicing in the country allows me 
to learn not only my patients' medical 
histories, but also their family histories 
and life experiences," he says. 
"The PSAP allowed me to complete 
training during my clinical years of 
medical school in rural areas, and also 
to conduct some interesting academic 
research," he says. "I was able to build 
relationships with my mentors on the 
Jefferson faculty, who showed me the 
scope of what you can do in family 
medicine." 
Turner put his training to work in a 
group medical practice in Lock Haven, 
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where he lives with his wife and two 
children. He provides comprehensive 
care—everything from treating 
patients for the flu to delivering 
babies, performing minor surgeries 
(such as suturing or mole removal), 
and casting minor fractures. 
Like all PSAP participants, Dr. Turner 
studied under a physician preceptor 
for six weeks in a rural part of 
Pennsylvania in his fourth year of 
medical school. He found the 
experience so beneficial that he has 
since served as a preceptor for current 
Jefferson students. 
"Being a preceptor has allowed me to 
experience the benefits of the PSAP 
from the other side," Turner says. "I 
was able to keep my teaching skills 
sharp, and to bond with my student 
in much the same way as I had with 
my advisor. The PSAP allows both 
students and teachers to learn the 
dramatic differences between the 
practice of medicine in Center City 
Philadelphia and rural 
Pennsylvania." (4) 
Technology Illuminates a Work of Art 
The university's Portrait of Professor Benjamin H. Rand, a major early 
painting by Thomas Eakins, was studied over the summer by experts from 
the Philadelphia Museum of Art using infrared refiectography. Above, Mark 
Tucker, chief painting conservator at the museum, aims a camera which 
produces a greatly magnified view on the monitor at left. Infrared light has 
the ability to penetrate layers of paint, revealing preliminary underdrawings 
and compositional grids that Eakins made on the canvas. This provides a 
new understanding of his working methods as an artist. The three Eakins 
portraits at Jefferson were among many of the artist's works studied by the 
team. Looking on during the process are curators, conservators, and photog-
raphers from the museum. Coordinating Jefferson's participation in the 
study was Julie S. Berkowitz, University Art Historian. 
Zalewski Appointed to William Wikoff 
Smith Professorship in Cardiac Research 
Andrew Zalewski CD'84, Professor of Medicine, has been appointed to the 
William Wikoff Smith Chair in Cardiac Research. Dr. Zalewski, who is the 
Director of Jefferson's Cardiovascular Research Center in the Division of 
Cardiology, is a leader in the field of vascular biology and interventional 
cardiology. He and his group have published extensively on the mechanisms of 
vascular repair under physiological and disease-related conditions. Under Dr. 
Zalewski's direction, Jefferson's Cardiovascular Research Center has become a 
nationally recognized program bridging basic sciences with clinically relevant 
issues of coronary restenosis, bypass graft disease, and atherosclerosis. 
A native of Warsaw, Poland, Dr. Zalewski received his M.D. degree from 
Warsaw Medical School, where he did his internship and residency. He has been 
associated with Jefferson since 1983, when he initially served as a Fellow in 
Cardiology. He is a member of the American Heart Association, the American 
Physiological Society, and the North American Vascular Biology Organization. 
The William Wikoff Smith Chair was established by the W. W. Smith Charitable 
Trust of Newtown Square, Pennsylvania. During this past year, the trust 
completed its commitment to endow the chair. "This grant was given as a 
reflection of Mr. Smith's exceptional vision and his desire to enhance medical 
excellence," said Mrs. Mary L. Smith, his widow and trustee of the Smith Trust. 
"It is an honor to be a partner with Jefferson and its professionals who are at the 
forefront of heart research." —Roslyn Levine 
Dr. Zalewski; Ms. 
Deborah J. McKenna, 
who is a member of 
the trust's staff and a 
daughter of Mrs. 
Smith; Mrs. Mary L. 
Smith; Mrs. Louise A. 
Havens, grant 
administrator of the 
trust and a daughter 
of Mrs. Smith; and 
University President 
Paul C. Brucker, M.D. 
29 	 JEFFERSON Medical College Alumni Bulletin 	 December 1999 
...fir 	 • :4, - 
•„ 
• - 4, 
President's Club Dinner Celebrates Successful Completion of the Jefferson 2000 
Mrs. Samuel M. V. Hamilton, longtime university trustee and Chairman of the Jefferson 2000 Fund capital campaign, was the honored guest at this 
year's President's Club dinner. The annual dinner dance, hosted by President 
Paul C. Brucker, M.D. and his wife Joan, was a glittering celebration of Jefferson's 
175th anniversary and the extraordinary philanthropy that recently brought the 
comprehensive fund-raising effort to a close, ahead of schedule and ahead of its 
$200 million goal. 
The event, which acknowledges Jefferson's most generous and loyal benefactors, 
was held Saturday evening, October 2, at the Crystal Tea Room. The evening's 
program paid tribute to Mrs. Hamilton for her exceptional philanthropic 
leadership at Jefferson, and recognized 22 new President's Club Fellows and 13 
new members of the Winged Ox Society. 
"One hundred and seventy-five years ago, our founders had a mission, and I am 
proud to say it has been fulfilled," Dr. Brucker said. "This is a very different 
world than it was in 1824. Both eras have their unique challenges, but I think our 
founders would be pleased to see how Jefferson has flourished." 
"We did it!" Mrs. Hamilton told the group. "The Jefferson 2000 Fund has reached 
its goal—in fact exceeded it. The grand total is $202 million in gifts and pledges." 
Jack Farber, Chairman of the Board of Trustees of Thomas Jefferson University, 
made a special presentation to Mrs. Hamilton. "We have you to thank, Dodo, for 
leading this campaign to victory," he said. "The more than $200 million you 
have inspired all of us to raise will benefit countless patients now and in the 
future, educate generations of physicians and other health care professionals, 
and advance vital research." 
Mr. Farber unveiled a photographic portrait of Mrs. Hamilton as a gift to her 
and her family. An identical one will be displayed at Jefferson, to be replaced 
later by an oil portrait of Mrs. Hamilton. 
"Dodo's steadfast support has had a major impact on this institution," Mr. 
Farber said. In addition to leading the successful Jefferson 2000 Fund campaign, 
Mrs. Hamilton has been a member of the Board of Trustees for 27 years, and a 
member of the hospital's Women's Board for more than 40 years. 
During the program, Mrs. Hamilton acknowledged special donors. "For over 
two decades, new Fellows of the President's Club have received gold-headed 
physicians' canes, symbolizing healing, and acknowledging their exceptional 
generosity," she said. In announcing the names of the new Fellows, benefactors 
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whose total support has been $50,000 or more, Mrs. Hamilton reported that 
there were a record number of canes to present. 
The 22 new Fellows of the President's Club include: postgraduate alumnus 
Thomas Connelly D'85; Mrs. Catherine Datz; Michael D. Ellis '70; Mr. and Mrs. 
John Estey; Martin Feldman '62; Mr. and Mrs. Stanford Frank; Mr. and Mrs. 
Robert French Jr.; Joshua Gold; George Hollander '39; Mr. and Mrs. Harold 
Honickman; W. Bosley Manges S'44; Alice T. Muffly; John J. Murray; Mr. and 
Mrs. Daniel Polett; Dr. and Mrs. Robert Poole III '53; Robert A. Shopbach, M.D.; 
Grafton F. Sieber '57; and Paul E. Stroup '52. 
Richard L. Steelman Ph.D.'77 attended the dinner and received his gold pin 
signifying membership in the Winged Ox Society, which honors benefactors 
who have contributed $10,000 or more to Jefferson in the previous fiscal year. 
New members this year are: Mrs. William M. Cashman; Dr. and Mrs. Eui K. 
Chung; Dr. and Mrs. Won S. Cynn; Edward A. Emmett, M.D.; Mr. and Mrs. 
Stephen Klein; Karl G. Klinges '56; Mr. and Mrs. Leonard Korman; Mr. Howard 
S. Kroop; Helyn L. Romberg; Mr. and Mrs. Frank Schreiner; Frederick A. 
Simeone, M.D.; and Mrs. Henry Stofman. 
Bottom row, from left: Dr. and Mrs. Robert Capizzi and Mrs. Hamilton; 
Mrs. Hamilton is congratulated on her portrait by Mr. and Mrs. Farber and 
Dr. and Mrs. Brucker; 
Mrs. Benjamin Bacharach with Dr. Bacharach '56, Associate Dean for Alumni 
Relations and Acting Executive Director of the Alumni Association; 
Mrs. James Kelly '39 with Dr. Brucker. 
Middle row: Dr. and Mrs. Stanton Smullens '61; 
James Stratton and Mr. Farber; 
Julian Feldman '58 with William Keane, M.D. and Ronald Bolognese, M.D.; 
Eric Hume ORS'83 with Dr. Brucker and Jerome Cotler '52 and Mrs. Hume. 
Top row: Dr. and Mrs. Poole; 
Mr. and Mrs. Michael Murray and Mr. and Mrs. James Datz; 
Mrs. James Corwin '56 with George Gowen '52 and Dr. Corwin; 
(between rows) Dr. Brucker and Mrs. Muffly; 
(at top) Dr. and Mrs. J. Wallace Davis '42 and Mrs. Stofman; 
(between rows) Marianne Ritchie '80 with Dr. and Mrs. Everett Gordon '37 and 
Stuart Gordon '81; 
Mr. and Mrs. Honickman. 
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A Holiday Gift for You and Jefferson 
The Charitable Gift Annuity 
Give by December 31, 1999, to save federal income taxes on April 15, 2000. 
You work hard to build financial security for yourself and those who depend on you. 
However, federal income taxes can take a significant bite out of your assets. 
There's Still Time — Jefferson Can Help You Save on Your 1999 Taxes. 
With a minimum gift of $10,000, you can establish a charitable gift annuity 
and benefit future generations of Jeffersonians while receiving: 
• A federal income tax deduction 
• Guaranteed income for life, a portion of which may be free of income tax 
Charitable Gift Annuity* Fixed life Income to John and Mary: 
$680 per year. 
A Portion May Be Tax Free. 
Income Tax Deduction: John and Mary Donor Charitable $3,309 
Ages: 70 & 70 1•10•n•••••n Gift Annuity 
and 
Asset Transfer: $10,000 Managed by Jefferson 
Reduced Capital Gains Tax 
 
Gift of Principal 
to 
Jefferson 
For a personalized charitable gift annuity calculation or more information, 
please call Frederick "Fritz" Ruccius or Lisa Watson toll-free at 1-877-JEFF GIFT [1-877-533-3443]. 
You may also email your questions to jeff trust@ mail. tju.edu 
or complete and send the attached business reply card to the Jefferson Development Office. 
A Jefferson Planned Gift: An Investment in the Future 
* This advertisement is for illustrative purposes only and is based upon the Federal tax laws in effect on September 30, 1999, and 
should not be construed as tax advice. The laws and regulations of individual states are not discussed. Please note that individual tax circumstances may vary 
and the laws are subject to change. We recommend you consult your own tax advisor before making any financial decisions. 
An Albanian boy watches the convoy of American army vehicles pass by 
(photo by Ben Starnes '92). 
Caring for the Ill and the Wounded in 
Kosovo 
Starnes (right) performing a diagnostic peritoneal lavage 
in the trauma resuscitation bay in Albania last spring 
Maus, Flanagan, 
and Rosenwasser 
Neurosurgery and Ophthalmology 
Collaborate on Sophisticated Operation 
n a combined operation that brought 
together state-of-the-art ophthalmology 
and neurosurgery, physicians at Will Eye 
Hospital removed a benign but recurring 
tumor from the optic nerve of patient 
Dolores Breskie. The five-hour operation 
had a sight-saving, as well as a life-saving, 
outcome for Ms. Breskie, who had already 
lost vision in one eye. 
"It was the third time the tumor had 
grown back," says Joseph Flanagan '63, 
Professor of Ophthalmology at Jefferson 
Medical College and the attending surgeon 
who had removed the earlier growths. "It 
wasn't malignant, but it was behaving the 
way a malignant tumor does—aggres-
sively," says Marlon Maus '85, an associate 
surgeon on the Wills oculoplastic service. 
"It had spread quickly, covering her optic 
nerve, her sinuses, and several muscles. It 
had also grown very large." 
So large, in fact, that by the time of the 
operation, the tumor was the same size as 
Ms. Breskie's eye, and it was pushing 
against it, causing it to bulge unnaturally. 
"Her appearance just added to her 
distress," says Dr. Flanagan. 
But it was the direction the tumor was 
taking that especially concerned the 
physicians. "It was growing dangerously 
close to the area of the brain where the 
optic nerve centers the orbit," Flanagan 
pr explains, "so it was likely to spread into 
the brain." It was also likely to cost her the 
vision in her good eye. 
orbit so they can be removed without 
disturbing the brain," says Robert 
Rosenwasser, M.D., Chief of the Division 
of Cerebrovascular Surgery and 
Interventional Neuroradiology at Jefferson 
and Wills. "But this one was very deep 
and very far back, almost resting on the 
optic nerve. That fact moved it into the 
category of brain surgery." 
Dr. Rosenwasser conducted the first part 
of the surgery, removing a portion of the 
skull and orbit, and slightly shifting the 
brain to enable the ophthalmic surgeons 
to reach the growth. 
"We were looking down at the eye," says 
Daniel Elizondo, M.D., an oculoplastic 
fellow who assisted in the surgery, "and 
could clearly see the tumor and all of the 
tissue it had covered." 
The next phase was Dr. Flanagan's, who, 
assisted by Dr. Maus, spent three hours 
removing the tumor. "It's a procedure that 
takes a lot of time because we try to get all 
of the tumor, or as much as possible," 
Flanagan explains. 
Once it had been removed, steps were 
taken by Dr. Rosenwasser to decrease the 
chance of its return and to preserve the 
eye. This required removing areas of the 
muscles and nerves which had been 
invaded. "Although she has no vision in 
the affected eye, it was very important to 
her not to lose her eye," Rosenwasser says. 
mong the Jeffersonians who 
contributed to humanitarian 
efforts in the Balkans this past spring is 
Benjamin Starnes '92. Starnes is senior 
surgeon of the 212th Mobile Army 
Surgical Hospital—the only remaining 
MASH in the U.S. Army—which was 
deployed to Tirana, Albania with Task 
Force Hawk in April 1999. They were 
the medical support for the proposed 
deep strike of Apache helicopters into 
Kosovo. In Albania they saw more than 
700 patients and did 
28 operative cases. 
Providing care was 
complicated by the 
sheer numbers of 
refugees. 
Starnes also 
journeyed to Camp 
Bondsteel in Kosovo. 
The MASH then 
moved to Macedonia 
to back up Task 
Force Falcon and 
the implementation 
of Kosovo Force, the 
NATO peacekeeping force. "The 
initials KFOR are painted on 
everything that has any connection 
with it," Starnes says. 
This fall Starnes was re-stationed in 
Heidelberg, Germany where he leads 
a general surgery service. His team is 
scheduled to return to Kosovo in 
March 2000 for six months as part of 
continued peacekeeping efforts. It's a 
matter of helping wounds to heal. 
Under these circumstances, the surgical 
approach changed, evolving into a 
procedure requiring both an ophthalmic 
surgeon and a neurosurgeon. Furthermore, 
unlike many of the ophthalmic/neurosur-
gical procedures done at Wills, it was 
going to be open-skull surgery. 
"We do a lot of ophthalmic tumor 
surgeries jointly, but most are only in the 
After the cranial closure by Dr. 
Rosenwasser, Drs. Flanagan and Maus 
rebuilt the bony area from the patient's 
forehead to the cheek that had been 
destroyed by the tumor. 
"We saw her four hours later and she was 
wide awake, alert, and feeling very well," 
Flanagan recalls. "I'm grateful they were 
able to save my eye," declared Ms. 
Breskie shortly afterward. 
Starnes (right) 
and a fellow 
surgeon in front 
of the MASH 
in Tirana 
IN MEMORIAM 
Howard E. Dicker '29 died February 6, 
1999. A member of the Alpha Omega 
Alpha Honor Medical Society, he was in 
general practice in South River, NJ from 
1931 to 1970. He is survived by his wife, 
Alice. 
Charles Duffy Sr. '30 died April 10, 1999. 
He was in general practice in New Bern, 
NC. He is survived by two sons and a 
daughter. 
Samuel," Bishko '31 died July 12, 1999. 
He was in general practice in Cleveland, 
OH. He is survived by a son and a 
daughter. 
Lucian J. Fronduti '34 died August 27, 
1999. Board certified in general surgery 
and a Fellow of the American College of 
Surgeons, he was Chief of the Surgical 
Service, Citizens General Hospital, New 
Kensington, PA. He is survived by his wife, 
Jean Rita, and two sons. Son Robert is 
Jefferson '66 and son Ronald is Jefferson 
'77. 
James N. Barroway '35 died September 19, 
1999. Board certified in pediatrics and a 
Fellow of the American Academy of 
Pediatrics, he was on staff at Cooper and 
Our Lady of Lourdes Hospitals, Camden, 
NJ. Later he served as the Health 
Coordinator for the Camden County 
Division for Children. He is survived by a 
son and a daughter. Son Robert is Jefferson 
'64. 
Charles W. Hoffman '35 died June 29, 
1999. He practiced obstetrics and 
gynecology in South Amboy, NJ. He was 
Chief of Staff and Chief of Obstetrics-
Gynecology at South Amboy Memorial 
Hospital. He is survived by four daughters 
and a son. 
Louis A. Wilder '37 died August 23, 1999. 
Although board certified in pediatrics, he 
practiced as a family physician in 
Abington, PA. He was on staff at Abington 
Memorial Hospital, Abington, PA and the 
Albert Einstein Medical Center, 
Philadelphia, and served as the Police 
Surgeon for Abington Township for 25 
years. He is survived by three daughters. 
Warren S. Shepherd '38 died July 14, 
1999. Board certified in family medicine, 
he practiced in Vancouver, WA. A Fellow 
of the American Academy of Family 
Practice, he was on staff at St. Joseph and 
Vancouver Memorial Hospitals, Vancouver, 
WA. He served as President, Clark County 
Medical Society in 1948. He is survived by 
his wife, Frances, two sons and two 
daughters. 
James L Gardner '41 died June 1, 1999. 
Board certified in general surgery, he 
practiced in Ellwood City, PA. A Fellow of 
the American College of Surgeons and a 
founding member of the American College 
of Abdominal Surgeons, he was on staff at 
Ellwood City Hospital, Ellwood City, PA, 
and Jameson Memorial and St. Francis 
Hospitals, New Castle, PA. He is survived 
by two daughters and four sons. Son James 
L. II is Jefferson '72 and son Stuart is 
Jefferson '79. 
Joseph" Rupp '42 died October 2, 1999. 
He was board certified in internal medicine 
and became a widely recognized endocri-
nologist. A revered teacher at Jefferson, he 
received the Lindback Teaching Award in 
1964, was selected by graduating Jefferson 
students to administer the Hippocratic 
Oath in 1967 and again in 1971, and had 
his portrait presented to Jefferson by the 
Class of '69. He was a prolific writer in the 
field of endocrinology. A Fellow of the 
American College of Physicians and a 
member of the Endocrine Society and the 
Society for Experimental Biology and 
Medicine, he became Professor Emeritus of 
Medicine on his retirement in 1981. He is 
survived by his wife, Romaine, three sons 
and two daughters. Son James is Jefferson 
'80 and son Michael is Jefferson '84. 
John" Hosay '43 died April 10, 1999. 
Board certified in urology and a Fellow of 
the American College of Surgeons, he was 
Chief of Urology at the Jersey City Medical 
Center and St. Francis Hospitals, Jersey 
City, NJ and served as President of the Staff 
at St. Francis Hospital. He held a faculty 
appointment as Associate Professor of 
Urology at the New Jersey College of 
Medicine and Dentistry, Newark, NJ. He 
received the St. Francis Hospital Medal of 
Honor in 1987 and was selected "Urologist 
of the Year" by the National Kidney 
Foundation in 1992. He is survived by his 
wife, Lois, four daughters and two sons. 
Thomas E. Pilla 5'44 died July 4, 1999. 
Board certified in internal medicine, he 
practiced in Huntingdon Valley, PA. He 
was on staff at Abington Memorial 
Hospital, Abington, PA. He is survived by 
his physician wife, Kathleen Scott, three 
daughters and a son. Son Timothy is 
Jefferson '82. 
Henry G. Gallagher '46 died March 27, 
1999. He was a family practitioner in 
Dallas, PA. We have no further information 
at press time. 
John" Meehan '47 died August 29, 1999. 
Board certified in internal medicine, he was 
an attending cardiologist at Holy Redeemer 
Hospital, Meadowbrook, PA. He is survived 
by his wife, Dorothy, four sons and a 
daughter. 
Harold Reviser '49 died August 21, 1999. 
Board certified in colorectal surgery, he 
was a Clinical Assistant Professor at 
Jefferson. He was also on staff at Methodist 
Hospital in Philadelphia. He was a former 
President of the Pennsylvania Society of 
Colon and Rectal Surgeons. He is survived 
by his wife, Bertha, two daughters and a 
son. 
Juan E. Veve '49 died August 29, 1999. He 
was in general practice in Fajardo, PR 
where he was highly regarded for his 
compassionate care and for his charity 
work among his patients. He was on stall at 
the Fajardo District Hospital and was a 
member of the Puerto Rico Medical 
Association. He is survived by his wife, 
Teresa, two sons and a daughter. 
Carl G. Pierce Jr. '50 died July 26, 1999. 
Board certified in family medicine, he 
practiced in Rehoboth Beach and Lewes, 
DE. He was a Fellow of the American 
Academy of Family Practice. He is survived 
by his wife, Meredith, three daughters and 
two sons. 
Michael B. Dooley '52 died September 2, 
1999. Board certified in radiology and a 
Fellow of the American College of 
Radiology, he was Chief of Radiology, 
Phoenixville Hospital, Phoenixville, PA 
where he also served as President of the 
Medical Staff in 1971. He held a faculty 
appointment as Clinical Assistant Professor 
of Radiology at Temple University School 
of Medicine. He was a former President of 
the Pennsylvania College of Nuclear 
Medicine, the Pennsylvania Radiologic 
Society, the Philadelphia Roentgen Ray 
Society, and the Chester County Medical 
Society. He is survived by his wife, Bettie, 
four sons and four daughters. 
William F. X Coffey Sr. '53 died 
September 23, 1999. An internist, he was 
on staff at Fitzgerald Mercy Hospital, 
Darby, PA. Interested in life insurance 
medicine, he served as Medical Director, 
Metropolitan Life. He also served as 
Chairman, Insurance Medicine Section of 
the College of Physicians of Philadelphia. 
He is survived by his wife, Roseanita, five 
sons and four daughters. 
John W. Stoker '55 died February 20, 
1999. Board certified in obstetrics and 
gynecology, he practiced gynecologic 
oncology in Altoona, PA. He was Chief of 
Obstetrics-gynecology at Altoona Hospital, 
and a consulting physician, Roaring 
Springs Hospital, Roaring Springs, PA. He 
served as President of the Blair County 
Medical Society in 1971-72. He is survived 
by his wife, Elaine, a daughter and a son. 
Maurice" WardJr. '63 died September 14, 
1999. He was a radiologist and practiced at 
the Brandywine Hospital and Trauma 
Center, Coatesville, PA. He is survived by 
his wife, Marie, two sons and two 
daughters. Daughter Kristine is Jefferson 
'91. 
Stanley." Yoder '64 died June 14, 1999. 
Board certified in orthopaedic surgery and 
a fellow of the American Academy of 
Orthopaedic Surgeons, he practiced in 
State College, PA. We have no further 
information at press time. 
Stanton M. Baynes '69 died May 5, 1999. 
Board certified in pediatrics, he practiced in 
Bensalem, PA. He was a senior attending at 
Frankford Hospital, Philadelphia, PA. He is 
survived by his wife, Maxine, and four 
sons. 
Postgraduate Alumni 
Has& Tanyol GE'54 died June 17, 1999. 
He practiced in Fort Washington, PA and 
was on staff at Germantown Hospital, 
Philadelphia, PA and Montgomery 
Hospital, Norristown, PA. His research on 
hypertension and hepatic cirrhosis was 
published. He is survived by his wife, 
Lamia, and three daughters. 
Benny G. Quinones-Alamo AN'82 died 
June 29, 1992, it has been ascertained. 
Other than he practiced in Rio Predras, 
Puerto Rico; we have no further 
information at press time. 
Faculty 
Hyman Menduke, Ph.D., Honorary 
Professor of Biochemistry and Molecular 
Pharmacology, died September 23, 1999. 
He was an expert in statistics and, for 35 
years, taught statistics at Jefferson and 
assisted with the analysis of medical and 
research data for clinicians and medical 
scientists. He is survived by his wife, Clara, 
a daughter, a stepson and a stepdaughter. 
William C. Stainbadt, M.D., Honorary 
Professor of Surgery, died August 19, 1999. 
He served as Chief of Surgery, Bryn Mawr 
Hospital, Bryn Mawr, PA and was a 
supportive and contributing teacher in 
Jefferson's surgical resident education 
program. He is survived by his wife, Sallie, 
two daughters and two sons. 
Margaret "Linda" Gonnella died 
September 16, 1999. She was the wife of 
Joseph S. Gonnella, M.D., Jefferson's Senior 
Vice President for Academic Affairs and 
Dean of Jefferson Medical College. A 
graduate of the University of Oregon, Mrs. 
Gonnella moved to Wallingford 30 years 
ago to raise her family. She received the 
Wallingford/Swarthmore school district All 
Service Award. Girl Scouts recognized her 
with the Outstanding Volunteer Award. 
Linda was a longtime board member and 
past President of the League of Women 
Voters of Central Delaware County. 
Linda was a strong supporter of 
Jefferson, including the Hospital Women's 
Board. She was active in the Faculty Wives 
Club and instrumental in organizing its 
annual art exhibit. 
Linda was loved by family, friends, and 
community for her generous and caring 
spirit. In addition to her husband, she is 
survived by a daughter, two sons, a sister, 
and a brother. 
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Alumni in Scranton and Wilkes Barre, Pennsylvania gathered to welcome 
Jefferson leaders on September 29, at a dinner hosted by Nicholas I. 
Ruggiero '66 (left) and Stephen E. Pascucci '48. 
4 Jay S. Greenspan, M.D., 
Director of Jefferson's 
Division of Neonatology, 
was the featured speaker 
at the recent Legacy 
Society reception. He is 
pictured with L. Roy 
Newman '49 and Mrs. 
Newman. The Legacy 
Society recognizes 
alumni and friends who 
have generously supported Jefferson through bequests, life income gifts, or 
other estate plans. The reception gave them the opportunity to talk with 
President Paul C. Brucker, M.D. and other Jefferson leaders. 
CLASS NOTES 
'28 
Paul G. Holsinger of Martinsburg, 
PA celebrated his 100th birthday on 
July 24. His grandson, Steve 
Holsinger, wrote a tribute that 
appeared in the Morrison Cove 
Herald. Dr. Holsinger has devoted 
many years to creating a compre-
hensive index of the Liebegott 
Collection for the Martinsburg 
Community Library. This index 
contains over 20,000 different names 
which he organized by hand. 
'30 
Leon L. Berns of Wynnewood, PA 
was featured in a large article in the 
Jewish Exponent, July 29, 1999. Dr. 
Berns is still practicing medicine in 
Philadelphia with his wife, Mildred, a 
registered nurse. Dr. Berns was also 
on the faculty at Jefferson for 63 
years teaching the art and science of 
anatomy to first year medical 
students. 
'48 
Charles W. Anderson of Norfolk, VA 
is now retired and no longer a 
medical examiner, but is still working 
in the city's clinic for sexually 
transmitted diseases two days a week. 
'56 
Warren M. Levin is Chairman of the 
Medical Advisory Board of the 
Survive Until a Cure Foundation, a 
national organization that promotes 
various alternative therapies for 
patients with terminal illnesses. Dr .  
Levin now has an office in suburban 
Connecticut in addition to New York. 
'59 
Albert C. Price of Lancaster, PA has 
retired from the practice of pediatrics 
but continues to be active as senior 
advisor to the Safe Kids Program in 
Lancaster County, which he founded. 
Dr. Price, a pediatric cardiac 
specialist, was the PA Safe Kids 
Outstanding Coalition Volunteer in 
1997. He was driven by the large 
number of children injured or killed 
in farm accidents. He and community 
leaders have worked together to 
promote farm safety locally and 
statewide. He has been recognized for 
his work among the Amish and 
Mennonite farm children. 
'60 40th Reunion June 10 
Herbert D. Reber continues to work 
at developing new treatments for 
heroin and cocaine addiction, a field 
in which he is one of the country's 
foremost experts. The unit he set up 
at Columbia University College of 
Physicians and Surgeons was ranked 
number one in the country this year 
by U.S. News and World Report. Dr. 
Kleber tells the Alumni Bulletin that 
he has "some promising new 
treatment leads but no breakthrough 
imminent." His unit has six major 
studies underway that are funded by 
the National Institute on Drug Abuse. 
Kleber is a Professor of Psychiatry at 
Columbia, and Medical Director of 
the Center on Addiction and 
Substance Abuse (CASA). His 
publications include The American 
Psychiatric Press Textbook of 
Substance Abuse Treatment (1994), 
which is widely used by profes-
sionals. 
'62 
William V. Harrer has been President 
this year of the Medical Club of 
Philadelphia. "Many of our members 
are in fact from New Jersey," explains 
Dr. Harrer, who lives in Haddonfield 
and practices at Our Lady of Lourdes. 
In January he is succeeded as 
President by Robert Reinecke, M.D., a 
Professor of Ophthalmology at 
Jefferson. 
'69 
Jay S. Skyler of Key Biscayne, FL has 
been elected to the Board of Directors 
of Amylin Pharmaceuticals, 
headquartered in San Diego. Dr. 
Skyler is Professor of Medicine, 
Pediatrics, and Psychology and Co-
director of the Behavioral Medicine 
Research Center at the University of 
Miami in Florida. He is also Director 
of the Operations Coordinating 
Center for the National Institute of 
Diabetes and Digestive and Kidney 
Disease's Diabetes Prevention Trial in 
Type One Diabetes. Dr. Skyler has 
served as President of the American 
Diabetes Association, and is currently 
Vice President of the International 
Diabetes Federation. 
Amylin Pharmaceuticals is a 
pharmaceutical company focusing on 
metabolic disorders. They specialize 
in preclinical characterization of lead 
molecules and demonstration of the 
proof of their applicability to human 
health. The company has pioneered 
research of the hormone amylin and 
is developing SYMLIN (pramlintide 
acetate), a synthetic analog of human 
amylin, for the treatment of diabetes 
in people using insulin. 
'70 30th Reunion June 10 
Michael Ellis has contributed very 
generously to Jefferson Medical 
College to create a new scholarship, a 
program which is vitally important to 
the college. The Ellis family tradition 
of giving to Jefferson has been 
continued by Michael's son Jeffrey 
Ellis '98 of Philadelphia. 
Martin A. Tobey of Fort Worth, TX is 
still practicing cardiology. He and his 
wife, Judy, recently traveled to 
Budapest, Prague, and Vienna on an 
opera holiday. 
'71 
Paul M. Fernhoff of Atlanta, GA is 
completing a sabbatical year at the 
Centers for Disease Control working 
on policies for newborn screening. 
'74 
David A. Brent of Pittsburgh, PA 
continues as a Professor of Psychiatry 
at the University of Pittsburgh, 
directing a clinical research center 
that treats depressed and suicidal 
adolescents. "My greatest joy profes-
sionally," he says, "is helping young 
people to succeed at research." 
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Leone 
Hughes 
Genetics of Nicotine Addiction 
May Explain Why It's Hard to Quit 
or many people, even if they know 
the health problems that smoking 
causes, quitting is next to impossible. 
And getting hooked in the first place 
happened awfully fast. Of approxi-
mately 50 million smokers in the U.S., 
three fourths say they are addicted and 
two thirds say they want to quit. After 
surgery for lung cancer, nearly half of 
those who survive resume smoking. 
Among those whose 
larynxes have been 
removed, no fewer than 
40 percent start smoking 
again. 
Assistant Professor of 
Medicine Frank Leone 
PUD'97 is trying to figure 
out why some people can "go cold 
turkey" on cigarettes and nicotine, 
while others remain slaves to their 
addiction. 
The reasons are many and complex. 
An intriguing theory is that nicotine 
addiction is due to a combination of 
both environmental influences and 
factors hardwired into the brain. 
Some people may be genetically more 
susceptible than others to become 
addicted to the nicotine in cigarettes. 
Dr. Leone is now using a clinical trial 
to tease out the subtleties of nicotine 
addiction, particularly the genetic 
factors. He and his colleagues are 
looking at 800 pairs of siblings who 
smoke at least one pack of cigarettes a 
day and are nicotine-dependent. Four 
hundred pairs will be seen at Jefferson; 
the others will be studied at several 
other sites. Ashwin Patkar, M.D. of 
Jefferson's Department of Psychiatry is 
principal investigator. 
The researchers are sampling genetic 
material from each sibling. "If you share 
a trait such as eye color, you're likely to 
share genes that control them," Leone 
says. "We're taking siblings who share 
a trait and looking for genes in those 
pairs that are present more frequently 
than would be expected. 
"What predisposes you to certain 
behaviors is genetics. Some people 
can smoke for years, and one day 
decide to quit and never go back. 
Others try and try and are never able 
to stop. It may be too simplistic to say 
that some people have 
willpower and some don't. 
We like to think of each 
person as free-willed, but 
the fact is much of our 
behavior is wired. 
"Despite similarities in 
nicotine levels in the 
blood, and in how people metabolize 
nicotine, they differ in their 
addictions," Leone says. He suspects 
that the behavioral trait for nicotine 
dependence may involve the genes 
that control how we perceive and 
process information. 
"There have been meaningful twin 
studies showing that identical twins 
reared apart are more likely to both 
smoke than fraternal twins reared 
apart. 
Dr. Leone and his coworkers hope to 
also conduct a study of unrelated 
people who share the behavioral trait 
to see if they share the same genes 
more frequently than those without 
the trait. 
"We might find that there are several 
genes that interact with each other. 
Genetics is additive. 
"Once we know the genes, we could 
figure out the biochemical pathway of 
the addiction," Leone says. 
"Ultimately, we'd like to find a drug 
that can inhibit the neural pathway 
involved in the need to keep lighting 
Philadelphia Medic 
Brady, Hughes, and 
he Philadelphia 
County Medical 
Society honored three 
Jeffersonians at its 
Awards Night in 
November 1999. 
Luther W. Brady Jr. R'55 
was recognized with the 
Strittmatter Award, the most presti-
gious prize of the evening. It is 
given for overall contribution to 
medicine or surgery. 
Dr. Brady is known 
widely as a leader in 
radiation oncology and as 
a scholar and patron of 
the fine arts. He is 
currently the Hylda 
Cohn/American Cancer 
Society Professor at the Medical 
College of Pennsylvania and 
Hahnemann University. Brady is 
the founder and Editor of 
the American Journal of 
Clinical Oncology and a 
member of the editorial 
boards of 11 journals. 
Dr. Brady has been 
president of nearly every Plotkin 
major professional 
society relating to his specialty, 
and continues to be honored 
internationally for his work. He has 
participated in many committees of 
the Philadelphia County Medical 
Society, including service as Chair 
of the Center City Branch, Chair of 
the Cancer Committee, and 
Delegate to the Pennsylvania 
Medical Society. 
Alumna Wins the Appel Award 
Tiffany A. Hughes '96, who 
remained at Jefferson after 
medical school for a one 
year residency in internal 
medicine, and is now a 
third year resident at 
Eastern Pennsylvania 
Psychiatric Institute, was 
presented with the 
PCMS's Appel Award. 
This is a monetary prize presented 
to a Philadelphia area psychiatric 
resident who submits the best paper 
on clinical psychiatry 
relating to an experience 
in therapy or in research. 
Resident Wins the 
C. Nelson Davis Award 
Randi L. Plotkin, M.D., a 
third year psychiatry 
resident at Jefferson, is 
the recipient of this year's C. Nelson 
Davis Award. This monetary prize is 
presented for the best paper relating 
to alcoholism or other addictive 
disorders affecting physicians. Dr. 
Plotkin's winning paper was 
entitled "Counter Transference in 
Two Settings: A Case Report." It 
focused on heroine abuse and 
addiction.4' 
al Society Honors 
Plotkin 
Dr. Brady's interests also 
include the arts. He serves 
on numerous boards 
including those of the 
Philadelphia Museum of 
Art, the Santa Fe Opera 
Foundation, and the 
Opera Company of New 
Mexico. 
Brady 
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She Can Be as Tough as Her Cases, 
Though Not as High-profile 
uestion: What do these people 
have in common? 
. John W. Hinckley Jr., attempted 
assassin of President Reagan 
. Jim Bakker, disgraced televangelist 
. Theodore Kaczynski, the Unabomber 
Answer: They all underwent psychi-
atric evaluation by Sally A. Johnson 
'76, one of the nation's most respected 
forensic psychiatrists. Johnson is 
Chief of Psychiatric Services and 
Associate Warden for Health Services 
at the Federal Medical Center in 
Butner, North Carolina. She teaches 
at Duke University in both the Law 
School and the School of Medicine, in 
addition to being on the medical staff. 
Defense lawyers said Kaczynski 
suffered from paranoid schizophrenia 
and had a phobia of being labeled 
mentally ill. Prosecutors countered 
that he was competent to stand trial. 
Kaczynski, who attempted suicide 
more than once and consistently 
refused to be examined by 
government psychiatrists, eventually 
capitulated and underwent an 
evaluation by Sally Johnson. He 
hoped to be found competent to act as 
his own trial attorney. 
Johnson determined Kaczynski was 
competent. Her report to the judge 
linked Kaczynski's mental illness and 
the Unabomb campaign. Consistent 
with other individuals with 
persecutory types of delusions, she 
wrote, he was resentful and angry, 
and fantasizes and actually does resort 
to violence against those individuals 
and organizations that he believes are 
hurting him. 
Sally Johnson's colleagues think her 
skills are superb. John Monahan, 
psychologist and law professor at the 
University of Virginia, says, "There's 
no question that the judge in the 
Kaczynski case chose [a forensic 
psychiatrist] well. Dr. Johnson is 
among the leading forensic 
psychiatrists in the country. 
She's known for her 
thorough evaluations and 
her balanced judgments. 
If anybody is up to this 
particularly challenging 
evaluation, Dr. Johnson is." 
And Walter Dellinger, a 
former U.S. Solicitor General 
and a professor at Duke Law 
School, says he has known 
few lawyers or physicians 
who were able to combine 
the necessary professional 
detachment with the general sense of 
humanity that he sees in Johnson. 
"So many people who go into this 
field are show people," says Dr. Keith 
Brodie, former Chair of the Psychiatry 
Department at Duke and former 
President of Duke University. They're 
flamboyant." But he calls Johnson 
"very low-key, unflappable, not 
pushy." Yet her evaluations make 
page one of the New York Times. 
Not surprisingly, Dr. Johnson 
received the United States Attorney 
General's Award for Distinguished 
Service in July 1998 in Washington. 
But while she obviously spends hours 
asking endless questions of her 
patients, she avoids answering 
questions from the public. "She's very 
intent about maintaining her profes-
sional integrity," her husband, 
William Johnson, a lawyer and a vice 
president of Carolina Power and 
Light, told the Raleigh, North 
Carolina News and Observer. She says 
"no" to Ted Koppel, the famed TV 
anchorman. "She never has given 
interviews and probably never will. 
And if I do, she will divorce me." 
Johnson is a captain in the U.S. Public 
Health Service assigned to the Federal 
Bureau of Prisons. At Butner, she 
clear by the nationally publicized 
lawsuit over care at the new maximum-
security facility in southern Illinois.) 
"Prisons have a population of 
individuals who are underserved," 
Johnson explains. "In a prison, you feel 
you can make a difference. What I like 
about the field has changed over time. 
My interest in psychiatry has always 
been in the treatment of psychosis. In 
prisons, certainly, you have ample 
opportunity to see psychosis. But more 
importantly, you get to follow patients 
over an extended time, which is 
something you rarely get to do in the 
general community. In prisons, you 
come to understand the course of 
illness, which is fascinating from a 
clinical standpoint." 
The difficulty, she says, is that there are 
many treatment-resistant patients. One 
challenge is trying to deliver health care 
services in a system (prisons) where 
health care is not the primary mission 
"It's necessary (assuring that the health 
care needs of prisoners are met), but it's 
not the major focus." Over the last few 
years, though, only part of Johnson's 
work has been clinical. She consults 
with prison systems around the country 
on establishing training programs and 
patient care programs. 
The next time a high-profile, baffling 
criminal is in the paper, look for Sally 
Johnson's name as forensic 
psychiatrist. 
manages all medical services for 1000 
inmates and serves as chief adminis-
trator for the 200-bed inpatient 
psychiatric hospital on site. Butner is 
one of three main psychiatry referral 
centers for males in the federal prison 
system. 
While she was a student at Jefferson 
Medical College, Johnson accepted a 
public health scholarship, which 
required two years of payback. She 
took her residency at Duke University, 
where she had brief experience with 
prison populations. She scheduled her 
Public Health Service work after 
residency and chose the Bureau of 
Prisons for payback. 
"Clearly prisons are an area of need in 
psychiatry," says Johnson, who refuses 
Ted Koppel, but kindly consents to an 
interview with the Alumni Bulletin. 
(This need at prisons is surely made 
Editor's Note: We Are Providing You the Health Policy Newsletter 
To keep Bulletin readers informed about Jefferson, while containing mail 
costs, another publication is being shipped with the Bulletin. We believe 
you'll find that the Health Policy Newsletter tells you about topics that 
supplement those in the Bulletin. The Health Policy Newsletter is shipped 
quarterly, and describes health policy questions that Jefferson is studying. 
Please let us know your thoughts by directing them to 
Attention: Editor, Alumni Bulletin 
Jefferson Medical College 
1020 Locust M-41 
Phila., PA 19107 
Phone: 215 955 7920 Fax: 215 923 9916 
Email: Malcolm.Clendenin@maiLtju.edu 
37 	 JEFFERSON Medical College Alumni Bulletin 	 December 1 9 9 9 
Do You Use E-mail? 
Please tell the Alumni Office your e-mail address. It will be kept confidential, 
and will only be used to inform you about Jefferson activities. 
Simply send a message to jmc-alumni.office@mail.tju.edu  
'77 
Margaret M. Dunn has been 
appointed Associate Dean for Faculty 
and Clinical Affairs at Wright State 
University School of Medicine, 
effective September 1999. 
Dr. Dunn is a Professor of Surgery at 
Wright State. She also has served as 
Associate Program Director of its 
integrated surgical residency and Co-
director of Surgical Education at 
Miami Valley Hospital. Dr. Dunn 
recently was elected President of the 
American College of Surgeons, Ohio 
Chapter, and is a past President of the 
Association of Women Surgeons and 
the Dayton Surgical Society. She is a 
recipient of the Wright State 
University Academy of Medicine's 
Award for Excellence. 
'80 20th Reunion June 10 
Haynes "Tim" Cates Jr. of 
Wilmington, DE has been appointed 
Chief of the Division of Urology at 
Christiana Care Health Care System 
(the former Medical Center of 
Delaware). This division of the 
Department of Surgery at Christiana 
has been on U.S. News and World 
Report's "Best of list for the past 
three years. Tim and his wife, Sally, 
are the proud parents of Burke, 12, 
and Kjell, 10. 
Charles J. Dunton of Jefferson's 
Kimmel Cancer Center answers 
women's questions online about 
gynecologic cancers in "Ask Our 
Expert" on the Jefferson Health 
System website (www.jefferson-
health.org). Dr. Dunton is an 
Associate Professor of Obstetrics and 
Gynecology at Jefferson. The web 
page enables browsers to ask Dunton 
questions online, and receive an 
online response within a week. 
Jefferson's gynecology program was 
named this year by U.S. News and 
World Report as among the best in the 
country. 
'84 
Maureen D. Francis has joined the 
faculty of Southern Illinois University 
School of Medicine as an Assistant 
Professor of Internal Medicine. She 
comes from Boonville Family Practice 
in Boonville, NC, where she was the 
Medical Director. Previously she was 
an Assistant Professor of Internal 
Medicine at the Uniformed Services 
University of Health Sciences in 
Bethesda, MD. 
'86 
Melissa Moore Brown of Flourtown, 
PA, was one of the featured speakers 
for the annual commencement and 
baccalaureate programs at Keuka 
College, Keuka Park, NY, where she 
is a member of the Class of '72. She 
presently serves as a member of the 
Keuka College Board of Trustees and 
is President and CEO of the 
Philadelphia Medical Press. In 
addition to her ophthalmology 
practice, she is cofounder of the 
Pennsylvania Physician Healthcare 
Plan. 
'89 
John J. Walsh IV and Eugenia 
Sarafidis Walsh are proud to 
announce the birth of Benjamin 
Christos, on June 23. Rita, age seven, 
Joseph, five, and Gabriela, three, are 
thrilled with their brother. John is 
now a hand surgeon and Assistant 
Professor of Orthopaedic Surgery at 
the University of South Carolina 
School of Medicine. Jenny returns to 
her previous position as Assistant 
Professor of Family and Preventive 
Medicine in January 2000 after an 
extended maternity leave. They live in 
Columbia, SC. 
'90 10th Reunion June 10 
John A. Osborne of Collegeville, TX 
has joined the staff at Baylor Medical 
Center at Grapevine. Dr. Osborne's 
specialty is cardiovascular physiology. 
Mohan Suntharalingam of Baltimore, 
MD was featured in the June issue of 
the AAMC Reporter, a national 
publication of the Association of 
American Medical Colleges. The 
article described "A Day in the Life of 
a Junior Faculty Member." Dr. Suntha 
is an Assistant Professor of Radiation 
Oncology at the University of 
Maryland. 
'92 
Diane L Ching of Ambler, PA 
is now a pediatrician at 
Meadowbrook Pediatrics and Holy 
Redeemer Hospital. She and Lynn 
Silver Nugent have gotten together 
a few times since both their 
children happened to attend the 
same preschool class last year. 
'93 
Dawn A. Demangone of 
Philadelphia, PA married Dr. 
Russell Yoon in October. Dawn is 
now the Assistant Residency 
Director in Emergency Medicine, 
and Co-director of Medical Student 
Education in Emergency Medicine 
at Temple University. 
Scott A. Rushton has joined the 
Department of Orthopaedic 
Surgery at the University of 
Pennsylvania Health System. Dr. 
Rushton specializes in complex 
spine surgery and has published 
several papers on the topic. He 
completed his residency in 
orthopaedic surgery at Jeff and 
performed a fellowship in spine 
surgery at University Hospitals of 
Cleveland/Case Western Reserve 
University. 
'94 
Shmuel Shoham is currently living 
in Brighton, MA and happily 
married to Ruth Polk, a fellow in 
infectious diseases at Boston 
Medical Center. He is involved in 
researching the immune response 
to fungi. 
'96 
Matthew R. Panahandeh was 
married in October 1998 to 
Michelle Rathgeb, one of his fellow 
residents in the Department of 
Medicine at the University of 
Pittsburgh. Jeffersonians in 
attendance included Josephl 
Murphy III, his best man, Stephen 
D. Moy, Jason G. Wilmoth, Mark 
A. Taylor, Jeff Namey, Brett Opel!, 
and Stephanie L. Archer. 
Scott Memorial Library privileges for medical college alumni including 
postgraduate alumni: You may obtain a library card from the Scott Memorial 
Library. On your first visit to the library, please present your blue plastic 
alumni identification card and one form of photo identification (such as a 
driver's license) at the circulation desk window located on the second floor of 
the library. A barcode will be attached to your alumni ID card for no fee, and 
you will be able to use it to borrow books and to avail yourself of many of the 
services of the library free of charge. 
Each time you visit the library, you will be required to show your alumni ID 
card to the security officer stationed in the lobby. You may also be required to 
produce photo identification. This is for the protection of the staff and patrons 
of the library. 
If you have misplaced your alumni ID card, you may call the JMC Alumni 
Office (215 955 7750). After we have verified your status in the alumni 
database, we will mail you an alumni ID card and a sheet listing the library 
services available to alumni library card holders. 
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Saulino 
Nation's First Clinical Trial of Methods 
to Treat Paralyzing Spinal Cord Injury 
Julie Toms Poludniak of Elkton, MD 
and husband, Tim, are proud to 
announce the birth of their first 
child, Sarah, born August 18. 
'97 
Charles P. McClure of Springfield, 
PA is serving as Chief Resident in 
Family Medicine at Bryn Mawr 
Hospital for 1999-2000. 
'99 
Amami V. Gennanwala was one of 
the senior medical students honored 
at Jefferson in 1998-99 with Beach 
Scholarships. He is now training in 
orthopaedics at Penn State Geisinger 
Health System in Hershey, PA. 
Postgraduate Alumni 
Yoogoo Kang AN'78 has been 
appointed the Samuel Israel 
Professor and Chair of 
Anesthesiology at Tulane University 
School of Medicine in New Orleans. 
Dr. Kang is one of several 
Jeffersonians recently appointed to 
important posts in anesthesiology, 
including Stephen E. Abram '70, 
who is now Chair of Anesthesiology 
at the University of New Mexico in 
Albuquerque. 
Dennis L. Priolo DR'88 has joined 
the Landmark Medical Center in 
Woonsocket, RI. Dr. Priolo is 
certified by the American Board of 
Radiology. 
Maromi Nei N'99 has been 
appointed a staff member of the 
Comprehensive Epilepsy Center at 
Jefferson, and Assistant Professor of 
Neurology. Dr. Nei recently 
completed a fellowship a the 
center, which is one of the largest 
epilepsy programs in the world and 
is directed by Michael Sperling, 
M.D. Dr. Nei is board certified in 
psychiatry and neurology. She 
completed a neurology residency at 
the Hospital of the University of 
Pennsylvania, where she received 
the Samuel Zeritsky Clinical 
Research Prize. Her research has 
been published in journals 
including Epilepsia and Neurology. 
The staff of neurologists, 
neurosurgeons, psychologists, and 
neuroscientists at Jefferson's center 
provide a wide array of services 
including video EEG monitoring, 
an internationally renowned 
epilepsy surgery program, genetic 
counseling, specialty care during 
pregnancy, neuropsychological 
evaluations, psychological care, 
cognitive rehabilitation, social 
support, and community education. 
Graduate Studies 
Clara M. Ambrus, Ph.D.'55 has 
been elected to the Board of 
Directors of Aethlon Medical, 
headquartered in San Diego. The 
inventor of the Hemopurifier line of 
blood purification products, Dr. 
Ambrus is the founder of Hemex, 
Incorporated, a subsidiary of 
Aethlon. A Research Professor of 
Pharmacology, Pediatrics, and 
Obstetrics-gynecology at SUNY-
Buffalo, she has expertise in 
hematology, thrombosis-
hemorrhage, respiratory distress 
syndromes, and immobilized 
enzymes. She has over 200 
scientific publications to her credit. 
first-ever randomized study to 
etermine the best therapy for 
treating a paralyzing spinal cord injury, 
began this fall at the Regional Spinal 
- Cord Injury Center at Magee 
Rehabilitation Hospital and Jefferson. 
Funded by the National Institute of 
Child Health and Human Development, 
the study will continue for five years. 
"Until now, there have been no scientific 
studies to define which mode of therapy 
works best for spinal cord injury," 
explains principal investigator John 
Ditunno Jr., M.D., Director of the 
Regional SCI Center. 
Patients who have sustained an acute but 
incomplete spinal cord injury will be 
eligible for the study. Approximately half 
of those who are treated at the Regional 
SCI Center fall into this category. 
Participants will be treated with either 
conventional therapy which utilizes daily 
mobility retraining, or a combination 
of conventional interventions 
and body weight-supported 
ambulation therapy. 
"We want to determine which 
type of therapy produces 
better ambulation status or 
walking ability," says Michael 
Saulino PM'97, Instructor in 
Rehabilitation Medicine and 
Assistant Director of Resident 
Education, "and whether motor skills 
are improved." 
The theoretical basis of body weight-
supported therapy is the concept of a 
central pattern generator. "This is based 
on a belief that the human spinal cord 
has an intelligence all its own that can 
generate steplike electrical patterns when 
exposed to sensations like walking," 
Ditunno explains. 
Patients must have sustained their spinal 
cord injury within eight weeks of taking 
part in the study, and have some feeling 
or movement below the position of the 
injury. Subjects undergoing the weight-
supported ambulation, which is done at 
Magee, are placed in a parachute harness 
and positioned over a treadmill. Once 
the treadmill belt is moving, the investi-
gation team, which includes physical 
therapists, assist in moving the patient's 
legs in a way that should optimize 
sensory inputs. Clinical research has 
shown that patients with certain types of 
SCI who undergo this type of therapy 
gain enhanced locomotor activity. 
Dr. Saulino anticipates that approxi-
mately 25 patients will be enrolled 
annually. The Regional SCI Center is 
one of five centers nationwide partici-
pating in the study. 
Jefferson, in affiliation with Magee, is 
designated as one of the nation's 18 
Regional Research Spinal Cord Injury 
Centers, and the only one in the 
Delaware Valley. It is also federally 
designated as a Model System SCI 
Center. 
Jefferson and Magee, along 
with MossRehab—all 
members of the Jefferson 
Health System—were 
named this year by U.S. 
News and World Report in 
its "America's Best 
Hospitals" issue as among 
the foremost rehabilitation 
programs in the 
nation—the only 
Philadelphia providers to achieve 
this honor. 
The Regional SCI Center, which has 
treated more than 2,500 individuals, 
provides a multidisciplinary system of 
acute care and rehabilitation. It offers 
services from the moment of injury, 
through acute and rehabilitation phases, 
to followup care and reintegration into 
the community. With over 70 percent of 
persons with SCI admitted within three 
days of injury, the center has 
demonstrated a mortality rate of five 
percent (as compared to a 17 percent 
national average) and has significantly 
reduced the severe secondary 
complications. 
Readers are encouraged to submit nominations for the Medical College 
Alumni Achievement Award: The Achievement Award Committee of the 
alumni association is charged with the final selection. Please direct curricula 
vitae and bibliographies of medical college graduates, including postgraduate 
alumni, whose professional activities are sufficiently outstanding to warrant 
consideration to "Attention: Achievement Award Committee," 1020 Locust 
Street M-41, Philadelphia, PA 19107. 
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